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AIM AND OBJECTIVE 
 
 
 To evaluate the Comparative oral bioavailability of Trospium Chloride 
tablet in Human volunteers. 
          
 
 The study objectives included: 
• Assessment of the bioavailability of test  product A while comparing with a 
reference product B in 6 normal, adult, human subjects under fasting condition. The 
bioequivalence assessed is to be assessed under  following pharmacokinetic 
Parameters: 
¾ AUC0-t,  
¾ AUC0-∞,  
¾ Cmax, 
¾  Tmax,  
¾ Kel, and  
¾ t1/2. 
• Monitoring of the adverse events and ensure safety of the subjects. 
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  CHAPTER 1 
INTRODUCTION 
                     The concern today is not just to provide elegant and accurate dosage form but also 
to ensure that optimum amount of drug reaches the target site. As an example, a specific drug 
may be prepared as a capsule or tablet, each with different excipients, coating and coloring 
agents, which may affect the release rate of the drug from the formulation. A thorough 
background of the fate of drug after its administration, the rate processes to which it is subjected 
in the body and its behavior after biotransformation are thus very essential in addition to the 
knowledge about its pharmacodynamics. 
                   Due to the growth of many pharmaceutical industries and due to the post GATT era 
2005 there is a tremendous increase in a number of new generic drug products and also there is a 
tremendous increase in the same type of drug products in the market. This phenomenal growth of 
the generic pharmaceutical industry and the abundance of multi source products have prompted 
some questions among many health professionals and scientists regarding the therapeutic 
equivalency of products, particularly those in certain critical therapeutic categories such as 
anticonvulsants and cardiovascular. 
                      These multi source pharmaceutical products need to conform to the same standards 
of quality, efficacy and safety as required of the originator’s (Comparator) product. Specifically, 
the multi source product should be therapeutically equivalent and interchangeable with the 
comparator (pharmaceutically equivalent or a pharmaceutical alternative) in a pharmacokinetic 
study with a limited number of subjects in one way of demonstrating therapeutic equivalence 
without having to perform a clinical trial involving many patients. The purpose of the 
bioequivalence study is that the bioavailability of the formulations under investigation is shown 
to be equal. Based on that conclusion therapeutic quality of the formulations are claimed to be 
identical. The latter means that both the beneficial and side effects are identical and are truly 
interchangeable. The bioequivalence study thus provides indirect evidence of the efficacy and 
safety of a multi source drug product. Often this will be the only evidence that the product is safe 
and efficacious. It is therefore crucial that the bioequivalence study is performed in an 
appropriate manner .  
New formulations of active drug ingredients or therapeutic moieties must be approved prior to 
marketing by the FDA. In approving a drug product for marketing, the FDA must ensure that the 
drug product is safe and effective. Through appropriately designed bioavailability studies, the 
performance of the formulation used in the clinical trials, provide evidence of safety and 
efficacy. Bioavailability and bioequivalence studies of drug products and drug product selection 
have thus emerged as critical issues in pharmacy and medicine during the last three decades. 
 
1.1 DEFINITIONS 
Bioavailability: The rate and extent to which the active ingredient or active moiety is absorbed 
from the drug product and becomes available at the site of action. 
Pharmaceutical equivalents: Drug products that contain identical amounts of identical active 
ingredient, i.e., the same salt or ester of the same therapeutic moiety, in identical dosage forms, 
but not necessarily containing the same inactive ingredients. 
Pharmaceutical alternatives: Drug products that contain the identical therapeutic moiety, or its 
precursor, but not necessarily in the same amount or dosage form or as the same salt or ester. 
Therapeutic equivalents: Drug products are considered to be therapeutic equivalents only if 
they are pharmaceutical equivalents and if they can be expected to have the same clinical effect 
and safety profile when administered to patients under the conditions specified in the labeling. 
Bioequivalence: The absence of a significant difference in the rate and extent to which the 
active ingredient or active moiety in Pharmaceutical equivalents or Pharmaceutical alternatives 
becomes available at the site of action when administered at the same molar dose under similar 
conditions in an appropriately designed study. 
 
1.2   GENERAL OBJECTIVES OF BIOAVAILABILITY STUDIES 
Bioavailability studies are important in the 
• Determination of influence of excipients, patient related factors and possible interaction 
with other drugs on the efficiency of absorption. 
• Development of new formulations of the existing drugs. 
 
1.3 HISTORY OF BIOAVAILABILITY  
 It is commonly observed that there are several formulations of the same drug, in the same dose, 
in a similar dosage form and meant to be given by the same route. Substitution of one product for 
another can be made provided they are equally effective therapeutically as the standard required. 
In order to ensure the clinical performance of such drug products, bioequivalence studies should 
be performed. 
The concept of bioavailability was initially introduced by Oser 1945, its problem has only 
recently been recognized and discussed, as a result of controversies involving chloramphenicol, 
digoxin and phenytoin. A change in formulation caused decreased bioavailability of digoxin in 
Britain and phenytoin intoxication in Australia.   
The development of analytical techniques, during the 1960’s, made possible the development of 
methods sensitive enough to allow quantification of drugs or metabolites, initially in the urine 
and afterwards in the plasma, making possible the evaluation and the comparison of 
bioavailability of different formulations, as well as demonstration that significant differences 
among them could occur.  
 After the legislation of compulsory drug registration in 1969, which facilitated the introduction 
of generic drugs in Canadian market, the “Drugs Directorate” of the “Canadian Fasteral 
Department of Health and Welfare” began to use bioequivalence as a measure to approve the 
registration of a drug during the 1970’s. In 1966, FDA found that out of 4000 formulations 
available in USA, more than 300 were ineffective. The availability of over 45,000 formulations 
of 5000 drugs in India, the recent interest in cheap generic formulations and availability of 
special; long acting formulations have made it imperative for the physician and pharmacist to 
consider and understand the influence of bioavailability on the therapeutic decisions[4].  
In 1977, FDA published the first guidelines for clinical research intending to guarantee data 
quality and clinical research subject protection. Between 1977 and 1981, new guidelines on 
Good Clinical Practices were published. In 1988, a consolidated code of Good Clinical Practices 
(GCP) was published by the FDA.  
Good Clinical Practices were also adopted in other countries: 
• 1985-Japan and Canada 
• 1986-UK 
• 1991-Australia and EU 
• 1995-Publication of the Code of Good Clinical Practices (GCP) by WHO.  
In 1996, the International Conference on Harmonization (ICH) with posterior amendments 
served as a basis for the conduction of clinical trials, according to similar norms and rules in 
different countries and in accordance with scientific and ethical standards.  
Central Drugs Standard Control Organization suggests that BA/BE data is required to be 
furnished with applications for the new drugs as required under schedule Y, depending on the 
type of application being submitted.  
WHO guidelines suggest that BE studies should be performed in compliance with the general 
regulatory requirement and good practices and good laboratory practices guidelines.  
Feldman and associates (1982) reported that patients on a high carbohydrate diet have a much 
long elimination half-life of theophylline due to the reduced metabolic clearance of the drug (t 1/2 
-18.1hr) compared to the patients on a normal diet  (t 1/2 -6.76hr).  
 
 
 FACTORS AFFECTING BIOAVAILABILITY 
 The systemic absorption of an orally administered drug in a solid dosage form is comprised 
of three distinct steps: 
• Disintegration of the drug product 
• Dissolution of the drug in the fluids at the absorption site 
• Transfer of drug molecule across the membrane lining the gastrointestinal tract into the 
systemic circulation .  
Any factor that affects any of these steps can alter the drug’s bioavailability and thereby it’s 
therapeutic effect. The various factors that can influence the bioavailability of a drug can be 
broadly classified as dosage form-related or patient-related. Some of these factors are listed in 
the table below: 
TABLE: 1.1 BIOAVAILABILITY FACTORS RELATED TO DOSAGE FORM 
PHYSICOCHEMICAL 
PROPERTIES OF THE DRUG 
FORMULATION AND 
MANUFACTURING VARIABLES 
Particle size 
Crystalline structure 
Degree of hydration of crystal 
Salt or Ester form 
Amount of disintegrant 
Amount of lubricant 
Special coatings 
Nature of diluent 
Compression force 
  
One of the most important factors that affect the dissolution rate of slowly dissolving substances 
is the surface area of the dissolving solid. Peak blood levels occurred much faster with the 
smaller particles than the larger ones, primarily as a result of their faster dissolution rate. Particle 
size can also have a significant effect on AUC.  
There are numerous reports of the effects of formulation and processing variables on the 
dissolution of active ingredients from drug products: an apparently inert ingredient may affect 
drug absorption. For example, magnesium stearate, a lubricant, commonly used in tablet and 
capsule formulations, is water-repellant. Its hydrophobic nature tends to retard drug dissolution 
by preventing contact between the solid drug and the aqueous GI fluids. Thus, increasing the 
amount of magnesium stearate in the formulation results in a slower dissolution rate of the drug 
and decreased bioavailability. The nature of the dosage form itself may have an effect on the 
drug absorption characteristics .           
The effect of food and type of diet on the bioavailability of erythromycin is shown in a study by 
Welling[12]. The absorption of the antibiotics is significantly reduced when it is administered with 
food compared with its absorption under fasting conditions. This reduced absorption is primarily 
a result of degradation of the acid-labile erythromycin due to prolonged retention in the stomach. 
Food more usually delays drug absorption without reducing the extent of absorption. This can be 
of major importance to the patient however, since the onset of drug action can be delayed or even 
abolished if therapeutic concentrations fail to be achieved in the plasma. Consequently such 
interactions do warrant a mention. Delay of the onset of therapeutic effect is particularly 
important regarding analgesics. Willis showed non steroidal anti-inflammatory drugs including 
aspirin, diclofenac and piroxicam are absorbed more slowly with food than in the fasted state . 
Though their bioavailability may not be reduced, this is unlikely to reassure the patient whose 
main concern is to be rid of the pain quickly. 
JJ Michnovicz demonstrated that smoking exerts a powerful inducing effect on the 2-
hydroxylation pathway of estradiol metabolism, which is likely to decreased bioavailability at 
estrogen target tissues. 
 
1.4 TYPES OF BA/BE STUDIES  
FASTING STUDY 
After an overnight fast of at least 10 hours, subjects are made to continue to fast for up to 4 hours 
after dosing. The drug product is administrated with 240±2 ml of water. 
 
 
FAST STUDY 
After an overnight fast of at least 10 hours, subjects are given a high calorie-high fat breakfast 30 
minutes prior to administration of the drug product (dosing). The drug product is administrated 
with 240±2ml of water. No food is allowed for at least 4 hours post-dose. Water can be allowed 
as desired except for one hour before and after dosing as per the protocol.  
CROSSOVER DESIGN 
In these type of study design, 
• Each formulation is administered just once to each subject and once in each study period 
• All the subjects do not receive the same formulation at the same time; in a given study 
period, they are administered different formulation.  
 
Period refers to the time period in which a study is performed. A two-period study is a study that 
is performed on two different days (time periods) separated by a washout period during which 
most of the drug is eliminated from the body. A sequence refers to the number of different orders 
in the treatment groups in a study . 
  
1.5 METHOD OF ASSESSING BIOAVAILABILITY 
 Bioavailability determinations are performed by drug manufacturers to ensure that a given drug 
product will get to its site of action in an adequate concentration. Bioavailability studies are also 
carried out to compare the availability of a drug substance from different dosage forms or from 
the same dosage form produced by different manufactures. Bioavailability can be measured by 
different methods mentioned below 
• Based on Plasma Drug Concentrations 
• Based on Urinary Excretion Data 
• Based on Acute Pharmacodynamic Effect 
• From Well- Controlled Clinical trials 
• From Dissolution studies 
In all the above mentioned methods Plasma drug Concentration is the direct and reliable method 
and it is more followed. 
BLOOD LEVEL STUDIES 
Blood level studies are the most common type of human bioavailability studies and are based on 
the assumption that there is a direct relationship between the concentration of drug in blood or 
plasma and the concentration of drug at the site of action. By monitoring the concentration in the 
blood, it is thus possible to obtain an indirect measure of drug response. Following the 
administration of a single dose of a medication, blood samples are drawn at specified time 
intervals and analyzed for drug content. A profile is constructed showing the concentration of 
drug in blood at the specified time points the samples are taken.  
The key parameters to note are: 
• AUC 
• C max 
• T max 
 
SINGLE-DOSE VERSUS MULTIPLE-DOSE 
  Most bioavailability evaluations are made on the basis of single-dose administration. The 
argument has been made that single doses are not representative of the actual clinical situation, 
since in most instances, patients require repeated administration of a drug. 
 At a steady-state, the amount of drug eliminated from the body during one dosing interval is 
equal to the available dose (rate in=rate out); therefore, the area under the curve during a dosing 
interval at steady-state is equal to the total area under the curve obtained when a single dose is 
administered. This AUC can therefore be used to assess the extent of absorption of the drug, as 
well as its absolute and relative bioavailability. 
Multiple-dose administration has several advantages over single-dose bioavailability studies as 
well as some limitations. 
ADVANTAGES OF MULTIPLE DOSE ADMINISTRATION 
• Eliminates the need for a long wash-out period between doses. 
• More closely reflects the actual clinical use of the drug. 
• Allows blood levels to be measured at the same concentrations encountered 
therapeutically. 
• Because blood levels tend to be higher than in the single-dose method, quantitative 
determination is easier and more reliable. 
LIMITATIONS 
• Requires more time to complete. 
• More difficult and costly to conduct (requiring prolonged monitoring of subjects). 
• Greater exposure of subjects to the test drug increases the potential for adverse reaction. 
 
 
1.6 PLASMA DRUG CONCENTRATION-TIME PROFILE 
A direct relationship exists between the concentration of drug at the bio-phase (site of action) 
and the concentration of drug in plasma. A typical plasma drug concentration-time curve 
obtained after a single oral dose of a drug and showing various pharmacokinetic and 
pharmacodynamic parameters is depicted in fig.1.1. Such a profile can be obtained by measuring 
the concentration of drug in plasma samples taken at various intervals of time after 
administration of dosage form and plotting the concentration of drug in plasma (Y-axis) versus 
the corresponding time at which the plasma sample was collected (X-axis). 
 
1                
Fig: 1.1 Typical plasma concentration-time profile showing pharmacokinetic and 
pharmacodynamic parameters 
 
The main pharmacokinetic parameters used for the bioavailability evaluation are: 
1.6.1. Peak Plasma Concentration (Cmax) 
The point of maximum concentration of drug in plasma is called as the peak and the 
concentration of drug at peak is known as peak plasma concentration. It is also called as peak 
height concentration and maximum drug concentration. Cmax is expressed in mcg/mL. The peak 
level depends upon the administered dose and rate of absorption and elimination. The peak 
represents the point of time when absorption rate equals elimination rate of the drug. The portion 
of curve to the left of peak represents absorption phase i.e. when the rate of absorption is greater 
than the rate of elimination. The section of curve to the right of peak generally represents 
elimination phase i.e. when the rate of elimination exceeds the rate of absorption. 
 
.6.2. Time of Peak Concentration (Tmax) 
The time for drug to reach peak concentration in plasma (after extravascular administration) is 
called as the time of peak concentration. It is expressed in hours and is useful in estimating the 
rate of absorption. Onset time and onset of action are dependant upon tmax.  
 1.6.3. Area under the Curve (AUC) 
 It represents the total in grated area under the plasma level profile and expresses the total 
amount of drug that comes into the systemic circulation after its administration. AUC is 
expressed in mcg/mL X hours. It is the most important parameter in evaluating the 
bioavailability of a drug from its dosage form as it represents the extent of absorption.  
1.6.4. Elimination Rate Constant (Kel) 
The decline in plasma drug concentration is only due to elimination of drug from the body (and 
not due to distribution), the phase being called as elimination phase. Elimination phase can be 
characterized by 3 parameters-elimination rate constant, elimination half-life and clearance.  
 
1.6.5. Elimination Half-Life (T½) 
It is also called as biological half-life, it is the oldest and the best known of all pharmacokinetic 
parameters and was once considered as the most important characteristic of a drug. It is defined 
as the time taken for the amount of drug in the body as well as plasma concentration to decline 
by one-half or 50% its initial value. It is expressed in hours or minutes.  
Two drugs show the same response if they reach the minimum effective concentration (MEC) at 
the same time and are considered to be bioequivalence if the mean AUC and mean Cmax of two 
products do not differ by more than 20%; the products are then considered to have same clinical 
effect in patients. The various pharmacodynamic parameters which influence the above 
mentioned pharmacokinetic parameters are: 
Minimum Effective Concentration (MEC) 
It is defined as the minimum concentration of drug in plasma required to produce the therapeutic 
effect. It reflects the minimum concentration of the drug at the receptor site to elicit the desired 
pharmacologic response. The concentration of drug below MEC is said to be in the sub 
therapeutic level. 
Maximum Safe Concentration (MSC) 
Also called as minimum toxic concentration (MTC), it is the concentration of the drug in plasma 
above which adverse or unwanted effects are precipitated. Concentration of drug above MSC is 
said to be in the toxic level. 
Onset of Action 
The beginning of pharmacologic response is called as onset of action. It occurs when the plasma 
drug concentration exceeds the required MEC. 
Onset Time 
It is the time required for the drug to start producing pharmacologic response. It corresponds to 
the time of plasma concentration to reach MEC after administration of drug. 
 
Duration of Action 
 The time period for which the plasma concentration of drug remains above the MEC level is 
called as duration of drug action. 
 
Therapeutic Range 
The drug concentration between MEC and MSC represents the Therapeutic range.  
 
 
 
          1.7   LIQUID CHROMATOGRAPHY- TANDEM MASS SPECTROMETRY 
(LC-MS/MS) 
Mass Spectrometry (MS) combined with the separation power of chromatography has 
revolutionized the way we do chemical analysis today. LC-MS is a powerful technique used for 
many applications which has very high sensitivity and specificity. Generally its application is 
oriented towards the specific detection and potential identification of chemicals in the presence 
of other chemicals (in a complex mixture). The API source can operate using  
• Electro spray (ESI),  
• Nanospray (NSI) or  
• Atmospheric pressure chemical ionization (APCI) techniques.  
 
In ESI, the sample solution is sprayed in a fine mist of charged droplets containing sample ions 
by application of a large negative or positive voltage (typically ±4.5 to ±5 kV). A flow of 
nitrogen drying gas is directed at droplets and individual positive or negative ions are produced. 
ESI accommodates a liquid flow of 1 mL/min to 1 mL/min. This ionization technique is very 
suitable for the analysis of polar, thermally labile molecules such as drugs, DNA, RNA, sugars, 
peptides, and proteins. 
 
NSI is essentially ESI operating at very low liquid flow rates of 100 nL/ml  to several micro-
liters per minute in static or dynamic modes. Static NSI is a self-sustaining direct infusion of a 
low volume of sample over an extended period of time (1 to 5 ml can be sprayed over 30 to 60 
min) and allows an investigation of a sample in MS and MS modes. There is no LC attachment 
and investigation and maintanance of the spray conditions is assisted with a constant gas 
backpressure. Dynamic NSI allows connectivity to micro and nano LC columns adding the 
advantage of a chromatographic separation. The technique provides a tool for the most sensitive 
analytical challenges.  
 
 
 
1.8 BIOANALYTICAL METHOD 
A bio-analytical method is a set of procedure involved in the collection, processing, storage and 
analysis of a biological matrix for a chemical compound. The availability of selective and 
sensitive bio-analytical methods is a prerequisite for the generation of reliable data on 
pharmacokinetics, bioavailability and bioequivalence of drugs. These methods should allow the 
quantification of drugs and their metabolites in biological matrices, e.g. plasma, urine, and 
cerebrospinal fluid and must be validated with respect to their reliability for the intended use. 
Bio-analysis frequently involves the measurement of very low analyte concentrations in complex 
and potentially variable matrices. Quantification of drugs and their metabolites in biological 
matrices currently is one of the most important applications of LC-MS.   
PURPOSE 
Bio-analytical method intended for the estimation of drugs in biological fluids and Developing 
suitable analytical method for, 
• Identification and Quantification of different drugs and their metabolites from 
biological fluids. 
• Uses of detection techniques that is highly sensitive and specific for the quantification 
of drugs . 
 1.9 METHOD DEVELOPMENT  
In the past years, method development for quantitative bio-analysis using LC-MS has changed 
significantly. While in the past most attention was given to finding the optimum mobile phase 
composition for the ionization technique selected, nowadays it is realized that parameters related 
to sample pretreatment, chromatography, analyte ionization  and mass spectrometric analysis are 
all strongly interrelated. One cannot change one parameter without influencing many others. The 
choice between electro spray ionization (ESI), Atmospheric pressure chemical ionization (APCI) 
or another ionization technique should be made on the basis of analytical results with spiked 
pretreated samples. Only in this way matrix effects can be properly evaluated. In addition, 
optimum solvent conditions in analyte ionization are generally less important that achieving an 
appropriate chromatographic separation . 
SAMPLE PRETREATMENT  
A wide variety of sample pretreatment methods are applied in quantitative bio-analysis using 
LC-MS. In general, the three major goals of sample pretreatment are, 
• Removal of unwanted matrix components, which may interfere in the LC-MS analysis, 
e.g., compounds with high surface activity and nonvolatile compounds like proteins and 
salts. 
• Pre concentrate or enrich the analyte to improve the limits of quantitation.  
Exchange the analyte into a (more) favorable solvent composition.   
 
TECHNIQUES  
PROTEIN PRECIPITATION 
Protein precipitation is a routine, high throughput bio-analytical sample preparation technique. It 
is used to remove proteins from biological fluid samples prior to the analysis of drugs and their 
metabolites by LC-MS/MS. The technique has wide applicability in bio-analysis from discovery 
support through to clinical studies. Historically, protein precipitation has been carried out in vials 
or collection plates, followed by centrifugation. Protein precipitation by 96-well filtration has 
more recently been used as a high throughput, easy to automate and alternative to the traditional 
approach. However, most filter plates require the plasma sample to be dispensed before the 
precipitating solvent is added. This approach can lead to filtrate breakthrough before 
precipitation is complete, resulting in cloudy extracts and blocked wells. 
LIQUID-LIQUID EXTRACTION (LLE) 
LLE is the direct extraction of biological material with a water immiscible solvent. The analyte is 
isolated by partitioning between the organic phase and aqueous phase. Partition or distribution of 
a drug between two immiscible liquid phases can be expressed in term of distribution coefficient. 
Partition coefficient is constant only for a particular solute at specific temperature and pair of 
solvent used. Liquid-liquid extraction is probably the most widely used techniques because the 
anaylte can remove a drug or metabolite from larger concentration of endogenous material that 
might interfere with the final analytical determination. The technique is simple, rapid and has a 
relatively small cost factor per sample when compared to other methods. The extraction 
containing drug can be evaporated to dryness and the residue can be re-dissolved in a smaller 
volume of a more appropriate solvent (mobile phase). Near quantitative recoveries (90 %) of 
most drug can be obtained through multiple or continuous extraction. 
SOLID-PHASE EXTRACTION 
In solid phase extraction the analyte is retained on solid phase sorbent while sample passes 
through, followed by elution of analyte with appropriate solvent. A typical SPE sorbent consists 
of 40-60 µm silica particles which are bonded with hydrocarbon phase. This bonding is achieved 
by reaction of chlorosilane with the hydroxyl group of silica gel to form silicon oxygen-silicon 
link. 
 
1.10 VALIDATION OF BIOANALYTICAL METHOD  
Linearity and Standard Curve  
A standard curve is the mathematical functional relationship between instrument response and 
known concentration of the analyte. Concentration of the chemical reference standard (CRS) 
substance should be justified on the basis of the expected range. A standard curve should include 
blank sample (without internal standard), zero sample (with internal standard) and six to eight 
non-zero samples covering the expected range, including LLOQ . 
 
 
Lower Limit of Quantification (LLOQ) 
The lowest standards on the calibration curve should be accepted as the limit of quantification if 
the following conditions are met, 
• The analyte response at the LLOQ should be at least 5 times the response compared to blank 
response. 
• Analyte peak (response) should be identifiable, discrete and reproducible with a precision of 
20 % and accuracy of 80-102 %. Normally it is taken as the 10% of Cmax of the drug. 
 
Calibration/ Standard curve/Concentration-Response 
The simplest model that adequately describes the concentration response relationship should be 
used. Selection of weighting and use of a complex regression equation should be justified. The 
following condition should be met in developing a calibration curve, 
• 20 % deviation of the LLOQ from nominal concentration. 
• 15 % deviation of standards other than LLOQ from nominal concentration.  
 
SPECIFICITY 
It is the ability of analytical methods to differentiate and quantify the analyte in the presence of 
other sample components. 
Analysis of blank samples for appropriate biological matrix was obtained from at least 6 
individual sources. Each blank sample should be tested for interference and selectivity should be 
ensured at the lower limit of quantification (LLOQ). 
ACCURACY 
The accuracy describes the closeness of mean test results obtained by the method to the true 
value of the analyte. 
 
 
PRECISION 
The precision describes the closeness of individual measurements of an analyte when the 
procedure is applied repeatedly to multiple aliquots of a single homogeneous volume of 
biological matrix.   
Precision is further subdivided into within-run, intra-batch precision or repeatability, which 
assesses precision during a single analytical run, and between-run, inter-batch precision or 
repeatability, which measures precision with time, and may involve different analysts, 
equipment, reagents and laboratories. 
It should include minimum three levels of the expected concentration range and minimum five 
replicate at each level. 
RECOVERY 
The recovery of an analyte in an assay is the detector response obtained from an amount of the 
analyte added to and extracted from the biological matrix compared to the detector response 
obtained for the true concentration of the pure authentic standards. 
Recovery pertains to the extraction efficacy of an analytical method within the limit of 
variability. Recovery experiments should be performed by comparing the analytical results for 
extracted samples at three concentrations (low, medium and high) with un-extracted standards 
that represents 100% . 
STABILITY 
The stability of an analyte in a biological matrix is a function of storage conditions, the chemical 
properties of the drug, the matrix and the container system. Stability procedure should evaluate 
the stability of the analytes during sample collection and handling, after long-term (frozen at the 
intended storage temperature) and short-term (bench top, room temperature) storage, and after 
going through freeze and thaw cycles and the analytical process. 
 
a.   Freeze and Thaw Stability 
Analyte stability should be determined after three freeze and thaw cycles. At least three aliquots 
at each of the low and high concentrations should be stored at the intended storage temperature 
for 24 hours and thawed unassisted at room temperature. When completely thawed, the samples 
should be refrozen for 12 to 24 hours under the same conditions. The freeze-thaw cycle should 
be repeated two more times, then analyzed on the third cycle. If an analyte is unstable at the 
intended storage temperature, the stability sample should be frozen at -700C during the three 
freeze and thaw cycles. 
b. Short-Term Temperature Stability 
Three aliquots of each of the low and high concentrations should be thawed at room temperature 
and kept at this temperature from 4 to 24 hours (based on the expected duration that samples will 
be maintained at room temperature in the intended study) and analyzed. 
c. Long-Term Stability 
The storage time in a long-term stability evaluation should exceed the time between the date of 
first sample collection and the date of last sample analysis. Long-term stability should be 
determined by storing at least three aliquots of each of the low and high concentrations under the 
same conditions as the study samples. The volume of samples should be sufficient for analysis 
on three separate occasions. The concentrations of all the stability samples should be compared 
to the mean of back-calculated values for the standards at the appropriate concentrations from the 
first day of long-term stability testing. 
d. Stock Solution Stability 
The stability of stock solutions of drug and the internal standard should be evaluated at room 
temperature for at least 6 hours. If the stock solutions are refrigerated or frozen for the relevant 
period, the stability should be documented. After completion of the desired storage time, the 
stability should be tested by comparing the instrument response with that of freshly prepared 
solutions . 
1.11. CALCULATION OF PHARMACOKINETIC PARAMETERS 
Calculation of AUC0-t  
The Area under curve (AUC0-t) is calculated by taking the average of two subsequent plasma 
concentrations (Ci and Ci-1) and multiplying that average by the time difference between the 
consecutive  measuring points (ti and ti-1 ) 
All these outcomes are then summed to render the AUC from 0 to the last measuring time point. 
This approach is called the linear trapezoidal approach. 
 
Calculation of Cmax  
 Calculation of Cmax is very simple; the highest concentration value is Cmax 
Calculation of Tmax 
 The time point corresponding to Cmax is the value of tmax. 
 Calculation of Kel and T½ 
The calculation of Kel is an essential part of any bioequivalence study. Elimination is a first order 
process and a natural log (ln) - transformation makes it possible to draw a straight line through 
the elimination phase. The slope of the regression line is equivalent to Kel or the elimination 
constant. 
 
Fig: 1.2 Natural log transformed plasma concentration time-curve showing a regression line 
through the elimination phase. 
The calculation of the half-life is rather simple. One simply divides 0.693 by Kel to obtain t½. The 
relationship between t½ and Kel : t½ = 0.5 Kel. The term 0.693 is derived from ln(0.5) = 0.693 
(ignoring signs). Kel describes the lowering of ln transformed plasma concentration per time unit 
to obtain correct estimate of t½.  
 
 
Calculation of AUCtot 
The next step in process is to extend the plasma concentration time profile to infinity to obtain 
AUCtot. The latter parameter is an estimate of total mass of drug present in blood and also serves 
as a guide for adequate sampling. 
To do so Kel is of course the most logical parameter, next to the last plasma concentration. Kel 
describes the loss of drug per time unit (/h) so division by of Clast (mg/l) results in ameasure with 
the unit mg/l*h, which is an unit for AUC. The outcome of this calculation is the AUC from t last 
to infinity (AUCtot ), to obtain AUCtot ,AUC0-t and AUCtot is added 
 1.12 STATISTICAL CRITERIA 
 After a bioequivalence study is conducted and the appropriate parameters are determined, the 
pharmacokinetic data must be examined according to a set of predetermined criteria to confirm 
or refute the bio-equivalency of the test and reference formulations. That is, one must determine 
whether the test and reference products differ within a predefined level of statistical significance. 
Since the statistical outcome of a bioequivalence study is the primary basis of the decision for or 
against therapeutic equivalence of two products, it is critically important that the experimental 
data be analyzed by an appropriate statistical test. 
In the early 1970s, bioequivalence was usually determined only on the basis of mean data. Mean 
AUC and Cmax values for the generic product had to be within +20% of those of the reference 
(innovator) product. . Although the 20% value was somewhat arbitrary, it was felt that for most 
drugs, a 20% change in the dose would not result in significant differences in the clinical 
response to drugs. 
 A relatively common misconception is that current regulatory standards still allow this 
difference of 20% in the means of the pharmacokinetic variables (Cmax and AUC) of the test and 
reference formulations. The FDA's statistical criteria for approval of generic drugs now requires 
the application of confidence limits to the mean data, using an analysis known as the two one-
sided tests procedure. This change came about as a result of the conclusion of the FDA 
Bioequivalence Task Force in 1986 that the use of a 90% confidence interval based on the two 
one-sided t-tests approach was the best available method for evaluating bio-equivalence. 
Westlake was the first to suggest the use of confidence intervals as a means of testing for 
bioequivalence. Recognizing that no two products will result in identical blood-level profiles, 
and that there will be differences in mean values between products, Westlake pointed out that the 
critical issue was to determine how large those differences could be before doubts as to 
therapeutic equivalence arose. A test formulation was considered to be bioequivalent to a 
reference formulation, if   
 
And by this procedure, if test and reference products were not bioequivalent (i.e. means differed 
by more than 20%), there was a 5% chance of concluding that they are bioequivalent.  
The current FDA guidelines are that two formulations whose rate and extent of absorption differ 
by -20%/+25% or less are generally considered bio-equivalent.  In order to verify that the -
20%/+25% rule is satisfied, the two one-sided statistical tests are carried out: one test verifies 
that the bioavailability of the test product is not too low and the other to show that it is not too 
high. The current practice is to carry out the two one-sided tests at the 0.05 level of significance. 
Computationally, the two one-sided tests are carried out by computing a 90% confidence 
interval. For approval of an ANDA, a generic manufacturer must show that the 90% confidence 
interval for the ratio of the mean response (usually AUC and Cmax) of its product to that of the 
innovator is within the limits of 0.8 to 1.25. 
Since these tests are carried out at the 0.05 level of significance, there is no more than a 5% 
chance that they will be approved as equivalent if they differ by as much or more than is allowed 
by the equivalence criteria (-20%/+25%). Since this test requires that the 90% confidence 
interval of the difference between the means be within a range of -20%/+25%, it is more 
stringent than simply requiring the comparison of the test and reference products' AUC and Cmax 
to be within the 80 to 125% range. If the mean response of the generic product in the study 
population is near 20% below or 25% above the innovator mean, one or both of the confidence 
limits will fall outside the acceptable range and the product will fail the bioequivalence test. 
Thus, the confidence interval requirement ensures that the difference in mean values for AUC 
and Cmax will actually be less than -20%/ +25%. It should be pointed out that the standards vary 
among drugs and drug classes. For example, antipsychotic agents may fall within a 30% 
variation and anti-arrhythmic agents may be allowed a 25% variation. 
The actual differences between brand and generic products observed in bioequivalence studies 
have been reported to be small. The FDA has stated that for post-1962 drugs approved over a 
two-year period under the Waxman-Hatch bill (1984), the mean bioavailability difference 
between the generic and pioneer products has been about 3.5%. In addition, 80% of the generic 
drugs approved by the FDA between 1984 and 1986 differed from the innovator products by an 
observed difference of only +5%. Such differences are small when compared to other variables 
of drug therapy and would not be expected to produce clinically observable differences in patient 
response. 
  
 
 
 
 
 
 
 
 
 
 
 
 
   CHAPTER -2  
OBJECTIVES OF THE PRESENT STUDY 
i. To evaluate the comparative oral bioavailability of Trospium Chloride tablet (each 
containing Trospium chloride 20 mg) with that of reference product SANCTURA 
(each containing Trospium chloride 20 mg) of in healthy, adult, male, human subjects 
under fast conditions. 
ii. To develop a bio-analytical method and to validate the Trospium Chloride content in 
human Plasma using the LC-MS/MS method. 
iii. To find out whether the test and reference products are biologically equivalent or not.   
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER-3 
           REVIEW OF LITERATURE 
 
     Pietzko et al., (1994) have reported on the Influences of trospium chloride and oxybutynin 
on quantitative EEG in healthy volunteers. And also they have examined the possibility of 
these two drugs produce changes in central nervous electrical activity in an open, prospective, 
phase I study involving 12 volunteers. The biological activity of both drugs was ascertained by 
continuous simultaneous recording of the heart rate. A decrease in heart rate was detected after 
oral administration of oxybutynin, and an increase was seen after i.v. administration of 
trospium chloride. The results suggest that trospium chloride is less likely to produce central 
nervous adverse effects than to oxybutynin..  
 
  Norman Zinner et al., (2004) have identified that the trospium chloride improves overactive 
bladder symptoms by a multi-center phase III trial and reported that it has no known drug-drug 
interactions, an advantage for patients taking many medications. Because these qualities may 
provide added benefit when treating patients with symptoms associated with overactive bladder 
and urge incontinence, and studied the effectiveness of trospium in treating these conditions. 
Trospium significantly decreased average frequency of toilet voids and urge incontinent 
episodes compared to placebo. It significantly increased average volume per void, and 
decreased average urge severity and daytime frequency. All effects occurred by week 1 and all 
were sustained throughout the study.  
 
  David ., (2003). have evaluated the clinical pharmacokinetics of drugs used to treat urge 
incontinence. Unfortunately, the pharmacological activity of the reagents is not limited to the 
urinary tract, leading to systemic adverse effects that often promote non adherence. Although 
the pharmacokinetics of flavoxate, propantheline, scopolamine, imipramine/ desipramine, 
trospium chloride and propiverine are also reviewed here, only for oxybutynin and tolterodine 
are there adequate efficacy/tolerability data to support their use in urge in continence. 
Tolterodine is metabolised via CYP2D6 to the active metabolite 5-hydroxymethyl-tolterodine 
and via CYP3A to N-dealkylated metabolites. Urinary excretion of parent compound plays a 
minor role in drug disposition. In addition, the use of alternative formulations may also 
facilitate adherence, not only by reducing the frequency of drug administration but also by 
enhancing tolerability by altering the proportions of parent compound and active metabolite in 
the blood. 
 
  Halaska et al., (2003). Have carried out controlled, double-blind, multi-centre clinical trial to 
investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor 
instability. The trial comprised a total of 358 patients with urge syndrome or urge incontinence. 
At intervals of 4–8 weeks, patients were physically examined with measurements of blood 
pressure and pulse rate, were questioned about any adverse events, checked for compliance and 
underwent relevant laboratory tests. The main symptom encountered in both treatment group 
was dryness of the mouth. For patients on trospium chloride, the estimated risk of an 
unexpected adverse event was 0.027 per patient per week for all adverse events and 0.009 for 
dryness of the mouth, resulting in a considerably lower risk during treatment given with 
trospium chloride than with oxybutynin. An overall assessment for each of the drugs reveals a 
comparable efficacy level and a better benefit risk ratio for trospium chloride than for 
oxybutynin due to better tolerability. 
 
  Franqoise et al., (2003) have validated the liquid chromatographic and gas chromatographic 
Methods. Applications to pharmacokinetics validation of analytical methods are important for 
the generation of data for   bioavailability, bioequivalence and pharmacokinetic studies. It is 
essential to use well defined and fully validated analytical methods to obtain reliable result s 
that can be satisfactorily interpreted. This manuscript is intended to provide guiding principles 
for the evaluation of a method's overall performance. For this purpose, all of the variables of 
the method are considered, including sampling procedure, sample preparation, 
chromatographic separation, detection and data evaluation. The criteria considered are as 
follows; stability, selectivity, limits of quantification and of detection, accuracy, precision, 
linearity, recovery and ruggedness. Models used for analytical calibration curves are explained 
in term of validity and limitations, along with a presentation of the most common statistical 
considerations used to validate the model.. 
 
  Konstanze et al., (2003) have carried the randomized, double-Blind Study of the Effects of 
Oxybutynin, Tolterodine, Trospium Chloride and placebo on sleep in healthy young 
volunteers. The central nervous effects of oral anti cholinergic may limit the success of 
incontinence therapy and patient compliance. Only a few studies investigating this topic are 
available. This study was conducted to determine whether oral anti-cholinergics alter sleep and 
psychometric test parameters. The proposed design is randomized, double-blind, crossover, 
placebo-controlled study. study participants are 24 healthy volunteers without sleep related and 
the results of rapid eye movement  sleep was the primary parameter of polysomnography. The 
REM sleep for oxybutynin was significantly lower than that for trospium chloride and lower 
than that for placebo The number combination test , the primary parameter of cognitive 
function, and the d2 test did not reveal any differences in reaction time. With regard to the 
other sleep parameters, the REM latency for oxybutynin was clearly higher than that for 
placebo, trospium chloride and tolterodine..  
 
  G.lose et al., (2001)  have evaluated the intra-vesical oxybutynin for treating incontinence 
resulting from an overactive detrusor .The use of oral oxybutynin for treating bladder 
hyperactivity is well documented  but despite its clinical efficacy, some patients cannot tolerate 
the systemic side-effects caused by the oral administration of oxybutynin. The intra vesicle 
administration of oxybutynin is an option for those who remain refractory to oral formulations, 
or who cannot tolerate the side-effects. The intra vesicle administration of oxybutynin 
minimizes the anti cholinergic side-effects whilst retaining clinical efficacy. 
 
  Peterlangguth ,et al., (1997) have reported on the the Intestinal absorption of the quaternary 
trospium chloride : permeability –lowering Factor and bio-availabilities for oral dosage forms. 
the  intestinal absorption mechanism, permeability and bioavailability of the para-
sympatholytic, trospium chloride has been investigated in vitro and in vivo in rats , in order to 
gain a better mechanistic explanation for the underlying cause leading to low bioavailability 
determinations were done in using-type chamber with rat Jejunum and human coca-2 cells. In 
vivo bioavailability and mass balance studied were done in rats. Absorption was studied from 
trospium chloride solutions in saline and from w/o micro emulsions and cyclo-dextrin complex 
formulation. The Absorption mechanism of trospium chloride across the intestinal epithelium 
is rather complex and involves p-glycoprotein – mediated secretion and saturable binding to 
intestinal mucus. Trospium permeability across the intestinal epithelium increases non linearly 
with rising drug concentration at the optical membrane, neither the  micro-emulsion nor the 
cyclo-dextrin formulations increase the permeability of trospium   in vitro , leading to lower or 
equal    bioavailability of these in vivo as compared with the aqueous solution control 
 
  Donald m. et al., (1999) have reported on the evaluation of a new once-daily formulation of 
oxybutynin for the treatment of urinary urge incontinence and to evaluated in a 16-center, 
single-treatment study once-daily controlled-release oxybutynin (Ditropan XL) for urinary urge 
incontinence. Two hundred fifty-six participants with urge incontinence or mixed incontinence 
with a significant urge component were treated. After baseline measurements, participants 
converting from conventional oxybutynin started Ditropan XL at their previous oxybutynin 
dose; others started at 5 mg/day. Doses were adjusted until participants reached a maintenance 
dose that produced continence or the best balance between continence and side effects. This 
dose was continued for 12 weeks. Effectiveness was assessed by urinary diaries. Effectiveness 
was achieved across all doses studied, with 70% of participants using maintenance doses of 5 
to 15 mg/day. Mean urge incontinence episodes per week decreased from 18.8 at baseline to 
3.9 in maintenance week 1, 2.7 in week 4, and 2.8 at the end of the study. For those 
participants who reported urge incontinence episodes at baseline but were free of urge 
incontinence at maintenance week 1, 31% remained free of urge incontinence at every 
subsequent assessment. Participants who converted from other medications showed 
symptomatic improvement after conversion. At some time during the study, 58.6% of 
participants reported dry mouth, with 23.0% of participants rating it moderate or severe. Only 
1.6% of participants discontinued the medication because of dry mouth. Ditropan XL treatment 
reduced the number of incontinence episodes. Maximum benefit was demonstrated by 
maintenance week 4 and was sustained through 12 weeks of maintenance therapy.  
   Darioush Dadgar et al., (1995) have reported the Issues in evaluation of bio-analytical method 
selectivity and drug stability four key issues were addressed: the statistical relevance of any 
selectivity test performed; a criterion for significant interference; experimental methods to 
establish selectivity; and criteria for acceptance. To ensure that compound integrity is 
maintained throughout the work-up process, statistically meaningful methods of stability 
evaluation which are associated with specific acceptance criteria are required. Suitable 
methods for evaluating stability of analyte and/or solutions of analyte, in process stability, 
processed sample stability, long term stability and freeze-thaw stability, as well as meaningful 
acceptance criteria, are presented 
 
 
 
 
  L. Cardozo  et al.,  (2000) have reported on the Efficacy of trospium chloride in patients with 
detrusor instability: a placebo-controlled, randomized, double-blind, multi-centre clinical trial 
the main objective to assess the efficacy and safety of trospium chloride in the treatment of 
detrusor instability, compared with placebo. Patients and methods In all, 208 patients were 
allocated at random to either trospium chloride or placebo in a double-blind clinical study; the 
patients were treated for 3 weeks .Uro-dynamic values were measured37 at the beginning and 
end of the treatment period. Adverse events were recorded on patient diary cards. a 
confirmatory adaptive procedure with one planned interim analysis was used to evaluate 
efficacy. Trospium chloride produced significant improvements in maximum cysto-metric 
bladder capacity and urinary volume at unstable contraction. The patients' assessment of 
efficacy showed significantly greater clinical improvement in the trospium chloride group than 
in the placebo group Furthermore,  trospium chloride  was well tolerated, with similar 
frequencies of adverse events reported in both groups . Trospium chloride (20mg twice daily) 
is an effective and safe option for the treatment of detrusor instability.    
 
   P. Lopez pereira et al., (2003) have investigated that trospium chloride for the treatment of 
detrusor instability in children, assessed the efficacy and most appropriate dosage of trospium 
chloride for managing bladder instability in children as compared with a placebo. a total of 58 
patients with bladder instability were allocated at random to 1 of 5 groups—10, 15, 20 or 25 
mg  trospium chloride, or placebo administered daily in a multi-center , randomized, single-
blind clinical study. Patients were treated for 21 days, and current symptoms, voiding diary and 
uro-dynamic values were collected at the beginning and end of the treatment period. All 
adverse events were recorded at the last visit. 50 patients treated with trospium chloride 41 had 
a positive therapeutic result versus only 3 of 8 patients with improvement in the placebo group 
 
 
CHAPTER-4 
TROSPIUM CHLORIDE DRUG PROFILE 
Trospium chloride is a quaternary ammonium compound which is used to treat overactive 
bladder and symptoms of urinary incontinence, frequency, and urgency. Trospium chloride is a 
fine, colorless to slightly yellow crystalline solid. The compounds solubility in water is 
approximately 1g/2ml.each capsule contains the following in active ingredients: sugar spheres, 
Metha acrylic acid copolymer, ethyl cellulose, hydroxyl propyl methyl cellulose, tri ethyl citrate. 
 
 
                           FIG: 4.1 MOLECULAR STRUCTURE OF TROSPIUM 
 
 
 MOLECULAR FORMULA   : C25H30NO3 
MOLECULAR MASS            : 427.9 
CHEMICAL NAME  : Spiro[8-azoniobycyclo[3,2,1]octane-8,1-pyrrolidinium]-3  -
[(hydroxydiphenyl-acetyl)-oxy] Chloride(1α,3β,5α)-(9Cl) 
PHARMACOLOGY: 
Acetylcholine receptors: 
The acetylcholine receptors are subdivided into Nicotinic and Muscarinic receptor subtypes. 
These receptors are also called as cholinoreceptor. The term cholinoreceptor means the receptors 
which respond to acetylcholine. 
I ) Nicotinic Receptors: 
The receptors located on neuromuscular junction (NMJ) and at all autonomic ganglia (including 
adrenal medulla) are nicotinic receptors. The nicotinic receptor subtype are classified as muscle 
type (NM) and neuronal type (NN) and central nicotinic receptors. 
II ) Muscarinic Receptors: 
The receptors present at the parasympathetic neuro-effector junction at all smooth muscles and 
glands are muscarinic cholinergic receptors. These receptors are currently divided into five sub-
types(M1,M2,M3,M4,M5). In-vitro receptor binding studies have demonstrated the selectivity of 
trospium chloride for muscarinic receptor over nicotinic receptors, and similar affinity for the M2 
and M3 muscarinic receptor subtypes. M2 and M3 receptors are found on the glandular and 
visceral smooth muscles. Their activation results in mainly excitatory effects, e.g., increase in 
sweating, bronchial and salivary secretions, the contraction of visceral smooth muscles.M1, 
M4,M5 receptors are largely confined to CNS but their functional role is poorly understood. 
 
MECHANISM OF ACTION: 
Trospium chloride is an antispasmodic, anti-muscarine agent.. Trospium works by blocking 
cholinergic receptors that are found on muscle cells in the wall of the bladder, hence it is said to 
have anti-cholinergic property. Normally a natural body chemical called acetylcholine acts on 
the cholinergic receptors under the body’s control and this causes the bladder muscle to contract 
and the bladder to empty. Sometimes the bladder muscle can contract uncontrollably, causing the 
bladder to empty too frequently or  
 unexpectedly Trospium chloride compete with acetylcholine or other muscarinic agonists for the 
common binding site on the muscarinic receptor (M1 to M5). Hence this drug is said to be 
competitive agonists of the action of acetylcholine and other muscarinic agonists. This 
antagonism is reversible and therefore the blockade by smaller doses of trospium can be 
overcome by the larger concentration of acetylcholine or muscarinic agonists. When trospium 
binds to muscarinic receptor it blocks all action that is brought about by acetylcholine or 
muscarinic agonists. As trospium blocks the cholinergic receptors on the bladder wall, it prevents 
the action of acetylcholine. This relaxes the bladder muscle and helps making the bladder more 
stable. 
 
FIG: 4.2 MECHANISM OF ACTION OF ANTIMUSCARINIC DRUG TROSPIUM 
CHLORIDE 
 
 
 
 
 
PHARMACOKINETICS: 
Absorption: After oral administration of the drug (Trospium chloride) less than 10% of dose is 
absorbed. Mean absolute bioavailability of 20mg dose is 9.6%.Peak plasma concentration (Cmax) 
occur between 5 to 6 hours post dose. A 3 fold to 4 fold increase in Cmax was observed for dose 
increases from 20 mg to 40mg and from 20mg to 60mg respectively. 
Distribution: Protein binding ranged from 48 to 78% depending upon the assessment method 
used, when a range of concentration levels of trospium chloride (0.5-100µg/L) were incubated in 
vitro with human serum. The ratio of  trospium chloride in plasma to whole blood was 1:6:1.This 
ratio indicates that the majority of   trospium  chloride is distributed in plasma. 
Metabolism: The metabolic pathway of trospium chloride in humans has not been fully defined. 
Of the dose absorbed following oral administration, metabolites account for approximately 40% 
of the excreted dose. The major metabolic pathway of trospium is hypothesized as ester 
hydrolysis with subsequent conjugation of benzylic acid to form azoniospironortropanol with 
glucaronic acid. 
Excretion: The plasma half life for trospium chloride following oral administration is 
approximately 35 hours. After oral administration of trospium chloride, a majority of dose was 
recovered in faeces (85.2%) and a smaller amount of dose (5.8%) in urine. Of the radioactivity 
excreted into the urine 60% was unchanged trospium. 
 
 
 
 
 
 
 
DRUG INTERACTIONS: 
Trospium is metabolized by ester hydrolysis and excreted by the kidneys through a combination 
of glomerular filtration .and tubular secretion. No clinically relevant metabolic drug-drug 
interactions are anticipated with trospium. However some drugs which are actively secreted by 
the kidney may interact with trospium by competing for renal tubular secretion. 
The concomitant use of trospium with other antimuscarinic agents that produce dry mouth and 
constipation and other anticholinergic effects may increase the frequency or severity of such 
effects. Trospium may potentially alter the absorption of some concomitantly administered drugs 
due to anti-cholinergic effects of gastro intestinal motility. 
Food interaction: 
Administration of Trospium immediately after a high fat content meal reduced the oral bio 
availability of Trospium Chloride by 35% for AUC(0-Tlast) and by 60% for Cmax. It is therefore 
recommended to take trospium on an empty stomach at least one hour before a meal. 
Alcohol interaction: 
Alcohol should not be consumed within two hours of Trospium administration. Alcohol may 
enhance the drowsiness caused by anti-cholinergic agents. 
TOXICOLOGY: 
EFFECTS ON DIFFERENT ORGAN SYSTEM: 
The effectiveness of trospium chloride varies according to the tissue.  
The following sequence of sensitiveness of different smooth muscles and glands toward trospium 
action. 
Sweat, Bronchial and Salivary glands >> Heart and Eye >> Bladder and Gastrointestinal tract>> 
Gastric glands. 
FIG: 4.3 EFFECT OF TROSPIUM ON DIFFERENT ORGAN SYSTEM 
 
 
 
Central Nervous System: 
Trospium chloride  as almost no detectable CNS effects in low doses. In therapeutic doses it has 
only mild stimulant effect on medulary centres in higher doses it stimulates higher cerebral 
centres and in toxic doses the central excitation becomes more prominent leading to restlessness, 
irritability, disorientation, hallucinations. With still larger doses, the stimulation is followed by 
depression leading to circulatory collapse, paralysis, coma and  respiratory failure leading to 
death. 
  Eye:  
Circular muscle of iris, ciliary muscle and lacrimal glands possess M3 receptors. When instilled 
in eye, trospium or other tertiary ammine antimuscarinic drugs, block M3 receptors present in 
pupillary constrictor muscle and produce mydriasis, which is a consequence of unopposed 
sympathetic dilator activity. Thus in true sense, this type of mydriasis is passive (indirect) 
mydriasis. As normal papillary responses being blocked, the eyes become unresponsive to light 
(lose of light reflects). 
Cardio Vascular System: 
With usual clinical doses trospium causes a transient bradycardia initially. The bradycardia is 
rarely significant(only 5 to 8 beats lesser per mininute than normal) and are usually absent after 
rapid injection. There are no changes in blood pressure or cardiac output. This bradycardia 
occurs due to blockade of M1 receptor, which releases acetyl choline sinoarticular node   
Higher dosage of  trospium dilate cutanious blood vessels, especially of the face. The mechanism 
of this anomalous response is not known. However this would happen either due to histamine 
release or due to direct compensatory vasodialotor activity of trospium.  
 Respiratory System: 
Both smooth muscle and secretory glands of the pulmonary airway receive vagal 
parasympathetic innervation and have predominantly M3 receptors. Trospium like drugs  inhibit 
secretion of nose, mouth, pharynx and bronchi  and thus dry the mucous membrane of the 
respiratory tract. This drugs also reduce the laryngospasm   during general anaesthesia. However, 
drying of mucus secretion and suppuration of muco-ciliary clearance are undesirable side effects 
of   trospium in patients with airway disease as this leads to the formation of mucous plugs which 
can dangerously obstruct the airflow and predispose the patient to infection  
Gastro Intestinal Tract: 
I) Gastric secretions: Trospium can reduce the basal secretion of gastric acid by 40-50%. The 
concentration of the acid  is not necessarily lowered as secretion of  HCO3ֿ   is also blocked 
along with H+. Not only the volume of secretion, but the total amount of H+, HCO pepsin, and 
mucin, are all reduced. The effects of trospium on salivary secretion in more marked. The mouth 
becomes dry and tus swallowing as well as talking becomes difficult.  
II) Motility:  Trospium is very effective in reducing the tone and motility of the gut, right from 
stomach to colon. This results in prolongation of gastric emptying time, decrease  in tone, 
amplitude and frequency of peristaltic movements.  
Genitourinary Tract: 
The smooth muscle of ureters and urinary bladder wall is relaxed by trospium and hence the 
voiding is slowed (urinary retention). The antimuscarinic drug have no significant effect on 
uterus, although these drugs cross placental barrier, the foetus is apparently not affected. 
 Sweat Glands: 
 Thermoregulatory sweating is suppressed by trospium. Sweat glands have M3 receptors and are 
innervated by cholinergic nerves which are sympathetic in origin. In adults the skin may become 
dry and hot but the rise in body temperature   results only in toxic doses. 
CONTRAINDICATIONS: 
Trospium is contraindicated in patients with Urinary retention, Gastric retention, or uncontrolled 
narrow-angle glaucoma and in patients who are at risk for these conditions. Trospium chloride is 
also contraindicated in patients who have demonstrated hypersensitivity to the drug or any of its 
ingredients. 
 
 
OVERDOSAGE: 
Anti-muscarinic drugs are widely used in the treatment of urinary incontinence. However these 
drugs lack selectivity for the bladder, and effects on other organ system may result in side 
effects. Over dosage with anti-muscarinic drugs including trospium chloride can result in severe 
anti-muscarinic effects. 
Symptoms: A 7-month-old baby experienced tachycardia and mydriasis after administration of a 
single dose of 10 mg trospium given by a sibling. The baby’s weight was reported as 5 kg. 
Following admission into the hospital and approximately 1 hour after ingestion of the trospium, 
medicinal charcoal was administered for detoxification. While hospitalized, the baby 
experienced mydriasis and tachycardia up to 230 beats/min. Therapeutic intervention was not 
deemed necessary. The baby was discharged as completely recovered the following day. 
Treatment: Over dosage with trospium may result in severe anticholinergic effects. Treatment 
should be provided according to symptoms and supportive care. In the event of over dosage, 
electrocardiogram monitoring is recommended. 
PHARMACOLOGY IN SPECIAL POPULATION: 
Special populations –Pharmacokinetics  
Gender: Studies comparing the pharmacokinetics in different genders had conflicting results. 
When a single 40 mg trospium dose was administered to 16 elderly subjects, exposure was 45% 
lower in elderly females compared with elderly males. When 20 mg trospium was dosed twice 
daily for 4 days to 6 elderly males and 6 elderly females (60 to 75 years of age), AUC and Cmax 
were 26% and 68% higher, respectively, in females without hormone replacement therapy than 
in males. 
Renal function impairment: Severe renal impairment significantly altered the disposition of 
trospium. A 4.5-fold and 2-fold increase in mean AUC and Cmax, respectively, and the 
appearance of an additional elimination phase with a long half-life (approximately 33 hours) was 
detected in patients with severe renal insufficiency compared with healthy, nearly age-matched 
subjects. The different pharmacokinetic behavior of trospium in patients with severe renal 
insufficiency necessitates adjustment of dosage frequency. The pharmacokinetics of trospium 
have not been studied in people with mild or moderate renal impairment   from 30 to 80 mL/min 
Hepatic function impairment: Cmax increased 12% and 63% in subjects with mild and 
moderate hepatic impairment, respectively, compared with healthy subjects. AUC was similar. 
Trospium must be used with caution in hepatic impairment dysfunction. 
Special populations-Safety and efficacy: 
Elderly: In 2 studies, the incidence of commonly reported anti-cholinergic adverse events in 
patients treated with trospium (including dry mouth, constipation, dyspepsia, UTI, and urinary 
retention) was higher in patients 75 years of age and older as compared with younger patients. 
This effect may be related to an enhanced sensitivity to anti-cholinergic agents in this patient 
population  
Pregnancy:. Trospium has been shown to cause maternal toxicity in rats and a decrease in fetal 
survival in rats administered approximately 10 times the expected clinical exposure (AUC). 
There are no adequate and well-controlled studies in pregnant women. Use during pregnancy 
only if the potential benefit justifies the potential risk to the fetus. 
Lactation: Trospium (2 mg/kg orally and 50 mcg/kg IV) was excreted, to a limited extent (less 
than 1%), into the milk of lactating rats. The activity observed in the milk was primarily from the 
parent compound. It is not known whether this drug is excreted in human milk. Exercise caution 
when administering trospium to a nursing mother. Use during lactation only if the potential 
benefit justifies the potential risk to the newborn. 
 Children: Safety and efficacy in pediatric patients have not been established. 
 
 
 
 
 
CHAPTER -5 
METHODOLOGY 
STUDY SITE 
 The study was conducted at WELLQUEST CLINICAL RESEARCH a division of PIRAMAL 
HAELTH CARE LIMITED.  
COMPANY PROFILE 
 Wellquest clinical research labs have a 52 bedded facility, located in Ramanthapur 
HYDERABAD. This unit conducts Bioavailability and Bioequivalence clinical studies on 
healthy human volunteers. The unit has been organized into various sections such as: Counseling 
Area, Examination Room, Fully Equipped I.C.U.(Emergency Room), Blood Sampling Area, 
Volunteer Housing Area, Dining Area, Recreation Area and Documentation Room. 
 
5.1  CONTRACT BETWEEN SPONSOR AND INVESTIGATOR 
At first, the sponsor takes responsibility for the initiation, management, and/or financing of a 
clinical study of a drug and signs a contract with a Contract Research Organization (CRO), 
for initiating and conducting the study. The investigator agrees and signs the protocol with the 
sponsor, and confirms in writing that he reads, understands and will work according to the 
protocol and Good Clinical Practice. The investigator is responsible for ensuring that the 
protocol is strictly followed. 
 
 
 
 
 5.2 PROTOCOL PREPARATION 
 After signing the agreement, the investigator starts preparing a protocol for the specific drug 
product which gives the background and rationale for the study. The contents of a protocol 
generally include the below mentioned topics: 
 
A. GENERAL INFORMATION 
• Protocol title, protocol identifying number, and date. Any amendment(s) also bear the 
amendment number(s) and date(s). 
• Name and address of the sponsor and monitor (if other than the sponsor). 
• Name and title of the person(s) authorized to sign the protocol and the protocol 
amendment(s) for the sponsor. 
• Name and title of the investigator(s) who is (are) responsible for conducting the study, and 
the address and telephone number(s) of the trial site(s). 
• Name(s) and address of the clinical laboratory and other medical and/or technical 
department(s) and/or institutions involved in the study. 
 
B. BACKGROUND INFORMATION 
• Name and description of the investigational product. 
• A summary of findings from non clinical studies that potentially have clinical significance 
and from clinical trials that is relevant to the study. 
• Summary of the known and potential risks and benefits, if any, to human subjects. 
• Description of the population to be studied. 
• References to literature and data that are relevant to the trial and that provide background 
for the trial. 
 
 
 
 
 
C. STUDY DESIGN 
The scientific integrity of the study and the credibility of the data from the study   depend 
substantially on the study design. A description of the trial design should include: 
• A description of the measured taken to minimize/avoid bias, including Randomization. 
• A description of the study treatment(s) and the dosage and dosage regimen of the 
investigational product. Also include a description of the dosage form, packaging, and 
labeling of the investigational product. 
• The expected duration of subject participation, and a description of the sequence and 
duration of all study periods, including follow-up, if any. 
• A description of the “stopping rules” or “discontinuation criteria” for individual subjects, 
parts of study and entire study. 
• Accountability procedures for the investigational product. 
 
D. SELECTION AND WITHDRAWAL OF SUBJECTS 
• Subjects inclusion criteria. 
• Subject exclusion criteria. 
• Subject withdrawal criteria. 
 
E. TREATMENT OF SUBJECTS 
• The treatment to be administered, including the name of the product, the dose, the dosing 
schedule, the route/mode of administration, and the treatment period(s), including the 
follow-up period(s) for subjects for each investigational product treatment/study treatment 
group/arm of the study. 
• Medication/treatment permitted (including rescue medication) and not permitted before 
and/or during the study. 
• Procedures for monitoring subject compliance. 
 
F. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
 The sponsor ensures that it is specified in the protocol or other written agreement that the 
investigator(s)/institution will permit study –related monitoring, audits, IRB/IEC review, and 
regulatory inspection(s), providing direct access to source data/document(s). 
G. INDEPENDENT ETHICS COMMITTEE (IEC) APPROVAL 
 After the protocol preparation for the particular study, Independent Ethics Committee approval 
is taken for conducting the study, whose responsibility is to ensure the protection of the rights, 
safety and well-being of human subjects involved in a trial and to provide public assurance of 
that protection, by, among other things, reviewing and approving/providing favorable opinion 
on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material 
to be used in obtaining and documenting informed consent of the trial subjects. The legal status, 
composition, function, operations and regulatory requirements pertaining to Independent Ethics 
Committees may differ among countries. After the IEC approval, the study process commences. 
 
5.3 STUDY CRITERIA RECRUITMENT AND SCREENING OF 
HEALTHY VOLUNTEERS 
 Volunteers were screened through a screening procedure within 29 days prior to the first dose 
administration or as specified by the protocol. The following medical tests were done during the 
screening process: 
• ECG 
• X-Ray 
• Laboratory tests (serology, hematology, urine analysis and biochemistry) 
 
 
 
INCLUSION CRITERIA 
• Healthy males aged between 18 and 45 years. Weighing at least 50kg and a body mass 
index of 18.5 kg/m2 and 24.99 kg/m2. 
• Completed the screening process prior to the study. 
• Subjects who have no evidence of underlying disease during screening medical history, 
physical examination, laboratory evaluation, ECG, X-ray recordings. 
• Willingness to provide written informed consent to participate in the study. 
• Availability of volunteer to the entire study period. 
• Willing to take non-vegetarian diet. 
 
EXCLUSION CRITERIA 
• History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, 
gastro – intestinal, endocrine, immunologic, dermatologic, neurological or psychiatric 
disease. 
• History of smoking more than 5 cigarettes per day or consumption of other forms of 
tobacco containing products. 
• History of alcohol intake more  than 3 units/day. 
• History of drug allergy to the test drug or any drug chemically similar to the drug under 
investigation. 
• Volunteers who have donated more than 450ml of blood in the past 3 months. 
• Subjects who have participated in another clinical study in the past 12 weeks of 
commencement of the study. 
 
WITHDRAWAL CRITERIA 
• Adverse event which warrants withdrawal of subject. 
• Concurrent medication. 
• Erroneous inclusion in study. 
• Failure to comply with restrictions and prohibitions. 
• Failure of drug administration. 
• Inadequate cooperation. 
Any subject withdrawal during the study shall be handled as per in-house procedure. The date on 
which the subject is withdrawn from the study and the reason for discontinuation will be 
recorded. 
 
RESTRICTIONS 
  Before entering into the study subjects have to follow below mentioned restrictions. 
• No subject should receive any medications [including OTC products], for the 7 days 
preceding the study. 
• Smoking should be prohibited from 24 hours before check in and until the subject leaves the 
facility. 
• The use of alcohol containing beverages should be prohibited for 48 hours before the check 
in process for all the periods and throughout the study period. 
• The use of caffeine/xanthine containing beverages and foods should be prohibited for 24 
hours before check in for all the periods and throughout the period of sample collection. 
• No grapefruit containing foods and juices should be permitted for 72 hours prior to check in 
all the periods. 
 
 
5.4 STUDY PROCEDURE 
The volunteers who met the inclusion and exclusion criteria were allowed to enter the study. 20 
volunteers were allowed to participate in the study as per the protocol requirement. 
 The study is of two periods and each period involves three stages: 
1. Check-in 
2. Dosing 
3. Check-out 
 
 
5.5 PERIOD-ONE 
5.5.1 CHECK-IN PROCEDURE 
            As soon as the volunteer reaches the clinical centre he was registered into the volunteer 
entry logbook and then will be counseled in-groups by the study counselor regarding: 
• Introduction of the research centre, 
• Brief explanation of Clinical Bio-studies (Bioavailability and Bioequivalence), 
• The purpose of such Clinical Bio studies, 
• Study procedure, 
• Number of blood draws, 
• Ambulatory blood draws, 
• Probable date of Check-in and Check-out, 
• Duration of stay in MTR, 
• Risks and benefits for volunteers, 
• Compensation to volunteers, 
• Volunteer rights, 
• Safety and confidentiality aspects, 
• Procedure for informed consent, and other details related to the particular study. 
Sufficient time is allowed after counseling for the volunteer to express his willingness to 
participate in the study. He was also informed that he is free to withdraw from the study any 
time they want.  
5.5.2 SIGNING INFORMED CONSENT 
Then an oral presentation of Informed Consent was done. Informed consent form is a process by 
which a subject voluntarily confirms his willingness to participate in a particular study, after 
having been informed of all aspects of the study that are relevant to the subject’s decision to 
participate. Informed consent is documented by means of a written, signed and dated informed 
consent form. 
 Volunteers are also given opportunities to ask their doubts and to make a decision. Copy of 
ICF is issued to the subjects and sufficient time is allotted to read and understand the content of 
ICF. 
The content of ICF includes study title, purpose and background of the study, study procedure, 
number of blood samples to be collected, restrictions to be followed before and after the study, 
adverse reaction of the drug, risks or discomforts associated with participation in the study, 
compensation, medical treatment for injury and rules and regulations to be followed. All the 
above points are discussed in detail in ICF. The healthy volunteers willing to participate in the 
study have to sign the ICF. They were given token numbers according to their arrival time to 
the centre and the token number is considered as the volunteer’s subject number. 
5.5.3 ELIGIBILITY ASSESSMENT 
 After their consent, the subject’s vitals (BP, pulse rate, temperature and respiratory rate) are 
checked by duty doctor. If subject’s vitals are normal and if the subject has followed all the 
restriction mentioned above, then the subject is eligible to participate in the study. 
5.5.4 VOLUNTEER HOUSING 
 The subjects are provided with separate lockers to keep their belongings and also a dress to 
change, along with a pair of slippers and other toiletries. After changing, the subjects are 
allowed to enter the housing area where the custodian discusses regarding Do’s and Don’ts 
with the subjects. Then subjects are provided with identity cards bearing their photos and other 
identification details like, subjects are provided with balanced standardized meal, which is 
planned by a dietician. 
5.5.5 DISPENSING OF DRUG 
The study drugs are stored according to the storage condition mentioned in the protocol. 
Temperature and humidity of the storage area is recorded at regular interval. The pharmacist 
dispenses the medicines a day before dosing in presence of quality assurance personnel. The 
dispersing of drug is done according to the randomization schedule and is pre-labeled (which 
includes subject number and study number) unit dose plastic container with lid and then the 
plastic containers are placed in a pre-labeled paper envelope. Drugs present in the plastic 
container are used during dosing process. 
5.5.6 DOSING 
On the dosing day, subjects are given a wakeup call by the custodian at a specific time and they 
are also given time to freshen up, after which they are called number wise for cannulation. A 
pre-dose sample was collected 1 hour prior to dosing which was called zero hour samples. 
Dosing was done in the morning, at the time mentioned in the protocol. The personnel 
designated and the clinical investigator was responsible for the dosing activity. Subjects are 
called in batches at pre assigned stations where the subjects receive single oral dose of 
(standard drug or test drug as per the randomization schedule) assigned formulation with 
240±2ml of water. The volunteers were administered with the drug product after the over night 
fasting, since the study is under fast conditions. Single tablet of Trospium chloride was 
administered in an empty stomach orally to the subject with 240±2 ml of water, in sitting 
posture at ambient temperature in the morning 
 
 
 
 
 
 
 
  
 
5.5.7 RANDOMIZATION 
The order of receiving the test and reference products for each subject during all the periods of 
the study will be determined according to a randomization schedule. The randomization 
schedule will be generated with the SAS software; version 9.1 package (SAS Institute Inc., 
USA).The randomization schedule will be kept under controlled access. 
                           TABLE:5.1 RANDOMIZATION SHEDULE 
SUBJECT NO SEQUENCE PERIOD 1 PERIOD 2 
S01 2 R T 
S02 1 T R 
S03 1 T R 
S04 2 R T 
S05 2 R T 
S06 1 T R 
  
 R - Reference; T – Test 
 
5.5.8 RESTRICTIONS: 
 The following restrictions were maintained in order to study and evaluate the absorption level 
of trospium chloride in plasma. 
• Pre dose fasting       -at least 10 hours 
• Post dose fasting     - 04 hours 
• Water restriction     -Pre dose and Post dose 01hour 
• Posture restriction   -04 hours post dose in sitting. 
• Caffeine such as coffee, tea, chocolate, and all caffeine containing soft drinks or energy 
drinks, alcoholic beverages, grapefruit was restricted for 48 hours prior to initial dosing 
and throughout the study until last scheduled blood sample collection. 
5.5.9    FOOD ADMINISTRATION: 
• Subjects were given lunch of 1100 kcal after 04 hours of dosing, snacks of      500 kcal 
at 08 hours post dose and dinner of 900 kc12 hours post-dose. 
 5.5.10 BLOOD SAMPLING AND HANDLING: 
• A total of 22 blood samples were collected during each period through an                      
indwelling intravenous cannulation placed in a fore arm vein. 
• The pre-dose samples were collected within 90 minutes before dosing and post- dose 
sample were collected within 2 minutes of the scheduled time. 
• The blood samples were collected using syringe and adaptor and transferred into pre-
S07 2 R T 
S08 1 T R 
S09 1 T R 
S10 2 R T 
S11 2 R T 
S12 1 T R 
S13 1 T R 
S14 2 R T 
labeled K2 EDTA vaccutainers placed upright in a rack kept in ice bath until 
centrifugation. 
• Intravenous indwelling cannula was kept in situ as long as possible by injecting 0.5ml of 
10 IU/ml of heparin in normal saline solution to maintain the cannula patent. 
• Blood samples were collected after discarding the first 0.5ml of heparinized blood from 
tubing. 
• The cannula was withdrawn after the collection of 24.00 hours sample or earlier if 
blocked. 
• The samples were withdrawn at the following time points 
TABLE: 5.2 BLOOD SAMPLING TIME POINTS 
S NO        TIME POINTS(Hours) 
1             1.00 
2 2.00 
3 3.00 
4 4.00 
5 4.33 
6 4.67 
7 5.00 
8 5.33 
9 5.67 
10 6.00 
11 6.33 
12 6.67 
13 7.00 
14 8.00 
15 9.00 
16            10.00 
17 12.00 
18 24.00 
19 48.00 
20 72.00 
21 96.00 
 
• The blood loss per subject for the entire study not exceeded 253ml.The split up is as 
follows. 
          010ml       -Screening prior to study 
          010ml       -Pre-dose blood draw (05 ml for each period) 
          210ml       -Blood draws (21 draws×2periods×05ml) 
          018ml       -Discarded blood (18 draws×2 periods×0.5 ml) 
          010ml       -Post dose investigations (05ml blood for each period) 
5.5.11 SUBJECT MONITORING 
Subjects were monitored throughout the study period for safety and adverse events. The 
following safety assessments were carried out to ensure the safety of Subjects. 
• Clinical examination and vitals – Before check in, before check out of each Period, during 
ambulatory visit and at any other time if necessary. 
• All post – dose vital sign measurements were recorded within ± 30 minutes of the 
scheduled time.  
• Subjects were questioned for well being at the time of recording of vital signs and at any 
other time if necessary. 
• Monitoring for adverse events - throughout the study period. 
 
    5.5.12 SEPARATION AND STORAGE OF BLOOD SAMPLES 
• The blood samples were collected at regular time intervals. The vaccutainers containing the 
blood samples are centrifuged at 4000±50 rpm for 10 minutes at 4ºC as early as possible to 
separate plasma. 
• In case of inadequate plasma, the samples was re-centrifuged 
• The supernatant matrix (plasma) was transferred into pre-labeled poly propylene tubes (RIA 
Vials). 
• Segregation was done as quickly as possible, as thawing may affect the quality of the sample 
adversely. 
• Separate racks for each subject were kept in trays containing ice pieces to accommodate the 
samples. 
• Samples were segregated according to the time point and subject numbers in corresponding 
racks. 
• Segregated samples were placed in pre-labeled zip lock covers and were stored in Ultra Low 
Temperature Freezer at -70ºC. 
 
5.5.13    CHECK-OUT  
On the next day of dosing, after ensuring that all the activities related to the study are completed, 
the cannula is removed. After the last blood draw and the investigator checked the vitals of the 
subjects. The check-out procedure was followed only if the health status of the subject is normal 
and here the subject is informed to contact the investigator in case of any medical problems 
related to the study. After this, subjects were given the locker keys and asked to change to their 
own clothes. They were checked out after partial payment was hanged over to the subjects at the 
end of the first period. The subjects are informed about the date of period – so that they can reach 
the centre at appropriate time for the second period. 
5.5.14 WASHOUT PERIOD 
Subsequent treatment is separated by periods long enough in order to eliminate the previous 
dose before the next one. The two phases of treatment are separated by an adequate washout 
period of 10 days which is ideally equal to or more than five half life’s of the moieties to be 
measured. 
 
 
 
5.6 PERIOD – TWO 
 After the specified washout period, the second period of the study begins, where the subjects 
again return to the centre at predetermined date and time. Apart from the informed consent 
process, the remaining same procedure is carried out, such that the two periods are identical in 
every manner. In period – two, the subjects those who had received test drug during period one 
will receive standard drug and the subjects who had received standard drug during period one 
will receive test drug. During this period Subject No: 11 didn’t come and he is considered as 
withdrawn from the study and it is documented.   At the end of the second period the subjects 
are provided with the full compensation 
 
5.7 ANALYTICAL PROCEDURE 
The Trospium Chloride test and reference product was compared using a validated Liquid 
Chromatography Mass Spectrometry method and according to the Bio-analytical laboratory’s 
standard operating procedures and other applicable guidelines. 
 
5.8 CHEMICALS USED 
• Acetone M (HPLC Grade). 
• Ammonium Formate (Analytical Grade). 
• Trospium chloride (Working standard). 
• Escitalopram oxalate (Internal standard) 
• Formic acid (Analytical Grade). 
• Acetone-M (HPLC Grade) 
• Milli-Q Water (HPLC Grade). 
• Ammonium acetate (GR Grade)                                   
 
    5.9 INSTRUMENT/EQUIPMENT USED 
• LC-MS/MS 
• HPLC 
• Deep Freezer 
• Vortex Shaker 
• Ultrasonic Bath 
• LV- Evaporator   
  5.10   Sample extraction procedure for Trospium Chloride 
• Plasma samples were removed from the ultra low temperature freezer before 30 
minutes of analysis and thawed to room temperature. 
• 1ml of the sample was pipetted out in RIA vials and vortexed for 2 minutes. 
• 50µl of International standard (IS) Esatilopram was added and then 400µl of Acetate 
in water was added and vortexed for 2 minutes. 
 
         Solid Phase Extraction: 
• Solid phase extraction was used to isolate analyte from the solution. 30mg/ml 
catridges was used for solid phase extraction 
 
Conditioning: 
• 100µl of Acetone-M   was added followed by 100µl of milli-Q water was added to 
condition the plexus 30mg/ml catridges. Conditioning was done to clean up the 
catridges before using the plasma samples. 
 
 
  Sample elution: 
• 1ml of the sample was then loaded into the respective catridges and allowed to elute 
by maintaining positive pressure under vaccum. 
 
  Washing: 
• The catridges were washed with 1ml of 5% ammonia in water and 1 ml of 1% formic 
acid in water. 
 
•  Selective washing was done to remove the impurities that were retained on the 
packing. 
 
• The catridges were then allowed to dry well and samples were  eluted using 0.5ml of 
1% formic acid in Acetone-M. 
 • The eluted sample was vortexed and transferred into a clean glass tube  
 
Positive pressure: 
 Positive pressure is a pressure within a system that is greater than the environment that 
surrounds the system. 
• The sample was then evaporated to dryness under nitrogen using LV evaporator for 15 
minutes at 40ºC and 15 psi pressure 
 
• The samples were then reconstituted by adding 0.4ml of mobile Phase. 
 
• The samples was then added into the glass vials and were Chromato- graphed in to the 
LC-MS/MS system along with quality control samples. 
 
 
 Table 5.3- Spiked Quality Control Samples of Trospium Chloride: 
Stock QC 
ID 
Stock 
Concentration 
(ng /ml) 
Stock 
Aliquot 
(ml) 
Diluent 
Added 
(ml) 
Final 
Volume 
(ml) 
Final 
Concentration 
(ng/ml) 
Spiked 
CCID 
QC 1 320.0000 0.2 9.8 10 6.4000 HQC 
QC 2 208.0000 0.2 9.8 10 4.1600 MQC 
QC 3 7.6960 0.2 9.8 10 0.1539 LQC 
QC 4 2.7321 0.2 9.8 10 0.0546 LLOQ 
 
 
 
 5.11     CHROMATOGRAPHIC CONDITIONS 
 HPLC conditions 
A summary of the chromatographic conditions is as follows: 
Column : Thermo, Hypersil GOLD, 150X4.6mm. 5u 
Mobile Phase  : Acetone-M, 2mM Ammonium Formate (60:40)   
Injection Volume : 8 µl. 
Flow Rate : 0.8 ml/min 
Column Oven temp : 40°C 
Auto sampler Temperature : 4°C 
Total Run Time : 3.5 minutes 
 
LCMS/MS conditions: 
Molecule :     Trospium(analyte)      scitalopram(Internal Standard)            
Q1 Mass (amu)  :             392.30                     325.20         
  
Q3 Mass (amu)  : 182.10                     262.10    
                
DP (Voltage) :  95.00                                           95.00      
               
EP (Voltage) : 10.00                     10.00   
CE (voltage) :  42.00                            26.00   
 
CXP (voltage) : 16.00                     16.00   
Source Conditions : 
GS1                                   :                   40 
GS2                                   :                    55      
Cur Gas                                  :                    30   
    
 
 
Data processing:  
Acquire chromatograms using the computer based analyst software supplied by Lab India 
Process data by peak area ratio. The concentration of the unknown is calculated from the 
following equation using regression analysis of spiked plasma calibration standard with the 
reciprocate of the drug concentration as a weighing factor (1 / concentration 2): 
Y = mx + b 
Where,  x = Concentration of Trospium 
  m = slope of the calibration curve  
  y = Peak area ratio 
  b = y – axis intercept of the calibration curve. 
 
5.12 PHARMACOKINETIC ANALYSIS 
The pharmacokinetic parameters Cmax, AUCtot, AUClast, Tmax, T½ of Trospium chloride were 
determined for test and reference product in each subject using kineticatm software (version 
4.4.1) 
 
Importing Files into Kineticatm 
• Primary concentration data from Excel sheet was imported into Kinetica Software using 
Import Assistant Wizard. 
• The Import Assistant Wizard is a series of dialogs that simplifies the importing of data and 
gives guidance through the step-by-step process. 
• All datasets in the Excel file contain the same time column but different concentration 
column for each subject. 
• XYi Data layout import method was selected and the source column called X and Y was 
inserted into the layout. 
• The Import Assistant terminates once the process was complete and the imported data was 
displayed in Kinetica. 
• The subject number (e.g. S01, S02………..), period (e.g. I, II…….), formulation (e.g. R or 
T) and the corresponding plasma concentration were entered in the appropriate dataset 
columns as per the Randomization schedule. 
• All Missing or Lost samples resulting from clinical operations or sample separation was 
denoted by ‘M’ wherever applicable. 
• The Missing samples were excluded from calculation of mean values. 
• Concentration below the Lower Limit of Quantification (LOQ) was reported as Below Limit 
of Quantification (BLQ) and was set to Zero for all Pharmacokinetic Analysis. 
• The pre-dose value less than 5% of Cmax and more than LOQ was considered for 
Pharmacokinetic Analysis.     
• The values more than 5% of Cmax were not included for Pharmacokinetic Analysis. 
 
AUC* 
 As a general practice, if the blood collection made beyond two mins of specified time, 
Pharmacokinetic Analysis were performed with the actual observed deviated time point. Such 
sampling time were tagged with an asterick(*) superscript wherever in the report table. 
AUC Steady-state 
All blood collection made within two mins of the specified time interval do not require any 
time correction for Pharmacokinetic Analysis. In such state AUC steady-state was selected. 
Pharmacokinetic Analysis 
                    The pharmacokinetic parameters were calculated and displayed in the data set view. 
• X and Y axis, Mean curve was selected from the chart wizard 
• The Appropriate concentration and time points were set to obtain the graph. 
• Linear and semi-log plots of mean plasma concentration Vs time were obtained 
 
CHAPTER-6 
                             RESULTS AND DISCUSSION 
6.1      LC-MS/MS ANAIYSIS OF TROSPIUM CHLORIDE 
The plasma concentrations of Trospium chloride were analyzed using a validated Liquid 
Chromatography Mass Spectrometry (LC-MS/MS) method. 
The concentrations of Trospium chloride present in 14 Healthy volunteers are summarized in the 
Table no: 6.1  
 6.2   PHARMACOKINETIC STUDY  
Import individual concentration corresponding to the time points with the dosing regimen data 
from Excel sheet to the KINETICAtm . The following pharmacokinetic parameters were 
obtained. 
1. Cmax 
2. Tmax 
3. AUClast 
4. AUCtot 
5. Kel   
6. T1/2                                                                                                                                                                   
Pharmacokinetic parameters obtained were listed in the Table no: 6.2 
 
 
 
 
 
 
Fig :6.1   Representative regression analysis of a calibration curve for trospium chloride  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table no 6.1 Individual concentration data of trospium chloride  units:( ng/mL) 
  TIME (in Hrs) S01 PI S02PI S03PI S04PI S05PI S06PI S07PI 
0.00 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
1.00 0.5770 2.3449 1.3326 2.0901 0.1785 2.4294 0.9969 
2.00 0.8890 3.1048 2.8566 5.0338 0.4461 3.3031 2.9081 
3.00 1.0211 3.5428 3.4381 8.6952 0.7557 2.5107 3.7501 
4.00 1.1714 3.8791 2.9129 NS 0.8012 2.0422 4.3342 
4.33 1.2760 4.8860 3.5873 12.0420 1.6302 2.2204 5.0459 
4.67 1.4271 4.3743 3.5193 9.8667 1.5787 5.2846 1.8550 
5.00 1.6064 4.0526 2.8575 8.9442 1.3316 1.6895 5.2333 
5.33 1.1216 2.6114 2.7052 10.6689 1.1983 1.4825 5.5575 
5.67 0.9614 3.6396 2.6684 8.9724 1.2832 1.3191 5.8779 
6.00 1.8201 3.4120 2.3946 8.9619 1.2518 1.1119 5.0066 
6.33 1.6608 3.0726 1.7461 2.9817 1.3081 0.9826 4.7752 
6.67 1.7244 3.6615 1.8135 NS 1.2189 1.0671 3.7142 
7.00 1.6413 2.8073 1.7846 6.9555 1.3062 0.9465 4.6555 
8.00 1.3617 1.9963 1.3418 6.2541 0.9310 0.7520 4.3564 
9.00 2.0863 1.3509 1.2425 4.9214 0.8237 0.6717 3.4011 
10.00 1.7267 0.9710 1.0076 4.9637 0.6694 0.6350 2.5519 
12.00 1.3838 0.7048 0.7958 3.5451 0.3915 0.5627 1.6970 
24.00 0.7006 0.4712 0.5212 1.5585 0.3839 0.3658 0.6536 
48.00 0.2648 0.2498 0.1501 0.4486 0.1274 0.1133 0.1473 
72.00 0.0926 0.0791 BLQ 0.2078 0.0513 BLQ BLQ 
96.00 BLQ BLQ BLQ 0.1115 BLQ BLQ BLQ 
TIME (in S01 PII S02PII S03PII S04PII S05PII S06PII S07PII 
(Cont
….) 
 
Indivi
dual 
conce
ntrati
on 
data 
of 
trospi
um 
chlori
de  
units:
( 
ng/m
L) 
 TIME 
(in Hrs) S08PI S09PI S10PI S11PI S12PI S13PI S14PI 
0.00 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
1.00 2.1076 0.1428 1.2060 1.1984 0.8414 0.7169 1.9011 
2.00 5.3097 1.0165 2.2498 1.2626 0.8342 1.8943 9.7236 
3.00 12.6009 1.8177 4.9956 1.4704 0.8514 2.6023 9.9273 
Hrs) 
0.00 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
1.00 0.5040 2.8967 0.3215 5.5960 0.1831 1.5350 0.9473 
2.00 0.3676 7.2057 0.5966 7.7037 0.3641 1.7713 1.9554 
3.00 0.4980 8.1366 0.6150 10.1613 0.7873 1.1843 3.1579 
4.00 0.5222 7.0044 0.5762 10.9047 1.0772 0.8533 3.2751 
4.33 0.8338 6.2226 0.8270 7.9557 1.8683 0.9258 4.3993 
4.67 0.6512 NS 0.7398 10.2039 1.6630 0.9250 4.8790 
5.00 0.9243 5.4882 0.6286 9.0009 1.4980 0.7395 4.7793 
5.33 0.9023 6.6018 0.5001 9.4218 1.2446 0.6381 4.1246 
5.67 0.8483 6.2384 0.5988 6.8259 1.2827 0.5869 4.4381 
6.00 0.8461 5.9172 0.4573 7.7172 1.2979 0.4909 3.6687 
6.33 0.8327 5.4714 0.4166 8.6784 1.3376 0.4576 3.7195 
6.67 0.7829 5.5634 0.3680 7.5386 1.4393 0.4670 4.6547 
7.00 0.7041 4.8595 0.4024 6.7966 1.3912 0.4092 3.5500 
8.00 0.6078 3.7379 0.3017 6.4568 1.2616 0.3816 3.2437 
9.00 0.5905 3.5561 0.2706 5.7658 0.9830 0.3541 2.6648 
10.00 0.4810 3.0126 0.1733 4.8553 0.7322 0.3033 1.9238 
12.00 0.3560 1.9234 0.2197 3.5779 0.6496 0.2564 1.3789 
24.00 0.2155 0.9215 0.1583 1.4892 0.3770 0.1899 0.4303 
48.00 0.1187 0.2534 BLQ M 0.1225 0.0803 0.0957 
72.00 0.0922 BLQ BLQ 0.1836 BLQ BLQ BLQ 
96.00 0.0596 BLQ BLQ 0.0987 BLQ BLQ BLQ 
4.00 7.7034 2.2651 7.1838 1.6227 0.9437 2.5890 9.3045 
4.33 14.3223 2.9133 10.1514 2.5151 1.4680 2.8641 12.6207 
4.67 13.6608 2.6122 11.8206 2.5976 1.6642 2.8311 11.7456 
5.00 11.1981 2.6449 9.4824 2.2752 1.4906 2.7395 9.3378 
5.33 10.8375 2.4109 8.8164 2.1127 1.3432 2.7176 8.0796 
5.67 7.9047 1.9542 10.1586 2.0667 1.1705 2.8477 7.8264 
6.00 8.8017 2.0662 8.2356 2.0750 1.2206 2.7855 6.9672 
6.33 7.7811 1.9375 7.1088 1.4361 1.2819 2.5893 7.4470 
6.67 6.8205 1.7206 7.4432 1.3365 1.1126 2.1379 4.9594 
7.00 6.6542 1.7416 7.0071 1.3577 1.0106 2.1542 5.6202 
8.00 5.6260 1.4244 6.7944 1.6330 0.8827 1.9877 5.9195 
9.00 5.2937 1.2385 5.9553 1.2597 0.7486 1.6476 5.3906 
10.00 3.9583 0.9998 4.8492 1.1563 0.5880 1.4603 4.9202 
12.00 2.9114 0.7813 3.2632 0.9020 0.3796 1.2858 3.4366 
24.00 1.1714 0.3753 1.4845 0.4994 0.2688 0.5581 1.9301 
48.00 0.3527 0.1321 0.4524 0.1755 0.0931 0.1328 0.5733 
72.00 0.1289 BLQ 0.1935 0.1157 0.0641 0.0641 0.2051 
96.00 0.0589 BLQ 1.6132 BLQ BLQ BLQ 0.1071 
   (Cont….) 
Individual concentration data of trospium chloride  units:( ng/mL) 
TIME (in Hrs) S08PII S09PII S10PII S11PII S12PII S13PII S14PII 
0.00 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
1.00 2.2375 0.2443 1.1960 0.6785 1.1815 0.4457 1.9003 
2.00 6.6993 0.9263 2.6488 1.4855 3.5995 0.5072 3.2659 
3.00 15.2682 2.3882 3.3098 2.0129 6.4744 0.5005 4.3511 
4.00 17.5230 5.1353 4.4937 2.5174 7.4998 0.4579 4.5258 
4.33 18.4716 6.8579 6.5431 3.6917 7.5354 0.5501 5.5326 
4.67 17.0349 6.6503 7.1651 3.5604 6.5028 0.5350 5.9529 
5.00 15.1839 6.4236 7.2021 2.9324 6.7126 0.5416 6.2613 
5.33 14.6109 5.9679 7.5661 2.9289 6.5573 0.4246 5.4292 
5.67 10.3215 4.5806 6.9466 3.0346 6.3512 0.3660 4.7900 
6.00 11.7495 4.8630 6.9895 3.1923 5.5900 0.3818 4.3627 
6.33 11.3001 4.6420 6.9291 3.3372 5.5445 0.3258 4.4526 
6.67 12.1164 4.3023 7.1009 3.5871 4.9037 0.3098 3.3846 
7.00 8.0967 4.1599 5.2683 3.3407 4.7043 0.3061 3.0967 
8.00 3.3477 NS 4.6891 3.3250 3.6513 0.2915 2.8013 
9.00 6.3480 3.2279 4.3297 2.5005 3.1404 0.2310 2.4803 
10.00 4.5070 2.4701 3.3625 2.1383 2.1975 0.2184 2.5000 
12.00 3.0476 1.8285 2.7307 1.9531 1.7582 0.1634 1.9336 
24.00 1.2981 0.7476 1.2232 0.8844 0.5478 0.1343 1.0231 
48.00 0.3273 0.2000 0.4618 0.3392 0.1348 0.0656 0.2970 
72.00 0.1099 BLQ 0.1952 0.1551 M BLQ 0.1522 
96.00 BLQ BLQ 0.0774 0.0700 BLQ BLQ 0.0769 
BLQ : Below Limit of Quantification ( 0.0513 ng/mL)    NS : Insufficient Sample    PI : Period 
One   PII: Period two    
   
Table no   6.2    Trospium pharmacokinetic data                          
 
Trospium pharmacokinetic data 
 
 
 
 
 
 
 
 
Study subject form dose Cmax Tmax AUC last AUC total K el T half 
Unit   mg ng/mL H (h)*(ng/mL) (h)*(ng/mL) 1/h H 
S01 PI 1 R 20 2.0863 9 44.5254 46.7614 0.041414 16.7369 
S01 PII 1 T 20 0.9243 5 18.5691 22.0531 0.017107 40.5183 
S02PI 2 T 20 4.886 4.33 48.7595 51.0323 0.034804 19.916 
S02PII 2 R 20 8.1366 3 87.5441 92.238 0.053986 12.8395 
S03PI 3 T 20 3.5873 4.33 38.7068 41.8095 0.048376 14.3282 
S03PII 3 R 20 0.827 4.33 7.01802 8.96286 0.081395 8.51587 
S04PI 4 R 20 12.042 4.33 140.714 144.508 0.029396 23.58 
S04PII 4 T 20 10.9047 4 155.724 158.29 0.038453 18.026 
S05PI 5 R 20 1.6302 4.33 23.0624 24.3284 0.04052 17.1063 
S05PII 5 T 20 1.8683 4.33 23.3967 26.1598 0.044335 15.6345 
S06PI 6 T 20 5.2846 4.67 29.5536 32.073 0.044972 15.4129 
S06PII 6 R 20 1.7713 2 14.5949 17.0464 0.032756 21.1612 
S07PI 7 R 20 5.8779 5.67 63.2641 65.5054 0.06572 10.5469 
S07PII 7 T 20 4.879 4.67 49.7936 51.0746 0.074707 9.27817 
S08PI 8 T 20 14.3223 4.33 127.558 129.167 0.036612 18.9321 
S08PII 8 R 20 18.4716 4.33 149.008 151.143 0.051486 13.463 
S09PI 9 T 20 2.9133 4.33 29.7072 32.429 0.048534 14.2816 
S09PII 9 R 20 6.8579 4.33 63.8033 67.107 0.060537 11.4499 
S10PI 10 R 20 11.8206 4.67 147.252 194.546 0.03411 20.3208 
S10PII 10 T 20 7.5661 5.33 104.448 106.55 0.036808 18.8313 
S11PI 11 R 20 2.5976 4.67 37.4792 40.3531 0.040258 17.2175 
S11PII 11 T 20 3.6917 4.33 68.2329 70.3878 0.032484 21.3381 
S12PI 12 T 20 1.6642 4.67 20.9436 23.0778 0.030035 23.0783 
S12PII 12 R 20 7.5354 4.33 70.7873 72.7891 0.067338 10.2935 
S13PI 13 T 20 2.8641 4.33 44.6933 45.9192 0.052288 13.2563 
S13PII 13 R 20 0.5501 4.33 8.36094 10.9241 0.025593 27.0835 
S14PI 14 R 20 12.6207 4.33 152.935 155.516 0.041487 16.7075 
S14PII 14 T 20 6.2613 5 80.7585 83.5319 0.027728 24.9979 
  
 
 
 
 
Criteria for Bioequivalence 
For Trospium chloride, based on the 90% confidence interval of the relative means Cmax, 
AUCtotal and AUClast of the test product to the reference product should be between 80 and 125% 
for log transformed data. If 90% confidence interval for the difference of log – transformed 
AUCtot, AUClast and Cmax lie within 80% and 125% then bioequivalence will be concluded. 
 
 
No. of Subjects: 14 
Table: 6.3 Pharmacokinetic statistical report 
 
Since the confidence interval does not lie within the acceptance range of 80 to 125%, the Test 
and Reference Products are not Bioequivalent for TROSPIUM CHLORIDE. 
 
 
 
 
 
6.3 PHARMACOKINETIC GRAPHS:    
Parameters 
Reference 
Confidence 
Interval 
90% standard confidence 
interval: 
[test form /ref form] 
Result 
Cmax 0.8 – 1.25 0.61741 – 1.4699 Cannot conclude equivalence 
AUC0-t 0.8 – 1.25 0.65451 – 1.5247 Cannot conclude equivalence 
AUC0-∞ 0.8 – 1.25 0.65364 – 1.4202 Cannot conclude equivalence 
The pharmacokinetic graphs generated for individual subjects with the help of KINETICAtm 
software are shown below:    Error! Bookmark not defined. 
Fig : 6.2      concentration Vs time graphs corresponding to  S1,S2,S3,S4   
Semi-long plots of individual subject plasma trospium :Concentration Vs time             
S1                                                          S2 
               
 
Semi-long plots of individual subject plasma trospium :Concentration Vs time 
S3,      S4 
                
 
 
 
 
Fig :6.3      concentration Vs time graphs corresponding to  S5,S6,S7,S8 
 
Semi-long plots of individual subject plasma trospium :Concentration Vs time 
S5      S6 
            
 
Semi-long plots of individual subject plasma trospium :Concentration Vs time 
S7       S8 
              
 
 
 
 
Fig :6.4      concentration Vs time graphs corresponding to  S9,S10,S11,12 
 
Semi-long plots of individual subject plasma trospium :Concentration Vs time 
S9       S10 
        
 
 
 
Semi-long plot of individual subject plasma trospium :Concentration Vs time 
S11      S12 
       
 
 
 
Semi-long plot of individual subject plasma trospium :Concentration Vs time 
Fig 6.5 concentration Vs time graphs corresponding to S13,S14 
 
S13        
       
 
S14 
 
          
 
 
 
   Fig:6.6  linear plot of trospium chloride conc vs time 
 
 
 
      Fig 6.7: semi log plot of trospium chloride 
 
 
 
 
DISCUSSION  
The main objective of the trial was to evaluate the single-dose oral 
bioequivalence and to monitor the adverse event of test product Trospium chloride in 
healthy, adult, human subjects. The clinical study was conducted with healthy, adult, 
human male subjects under fasting conditions. The Subjects in the age group 18-50 
years and who met the other study eligibility criteria were enrolled and completed the 
study.  
The safety, pharmacokinetics and performance profiles of Trospium chloride 
Test product was evaluated and compared with those of the commercialized reference 
formulation of Trospium chloride. The effect of Trospium chloride under oral 
administration to 14 healthy human male subjects was safe and equally well tolerated. 
Bio-analytical data were available after analysis of the samples at the Bio-analytical 
Department. 
 The PK Analysis result indicates that the 90% confidence interval does not lie 
within the acceptance range of 80 to 125% for Trospium chloride.  
From the above results and PK analysis the reference and test product of the Trospium 
chloride is considered to be biologically not equivalent. There are so many factors 
played a very important role in the present bioavailability study. These factors include 
No of subjects ,Dose, Sampling time points, Randomization Protocol deviations, 
formulation variation not only these every parameter have its importance in BA/BE 
studies and finally all these parameters play a key role in final result.  
 
 
 
 
 
 CHAPTER-7 
CONCLUSION 
The safety, pharmacokinetics and performance profiles of trospium test product was evaluated 
and compared with those of the commercialized reference formulation of trospium chloride. 
The effect of trospium chloride under oral administration to 14 healthy human male subjects 
was safe and equally well tolerated. Based on the PK results, the 90% confidence interval does 
not lie within the acceptance range of 80 – 125% for trospium.  The reference and test product 
of the drug is considered biologically not equivalent since they resulted in highly variable rates 
and extents of exposure of trospium. Overall, the test formulation of trospium chloride has a 
number of disadvantages over the conventional reference formulation of trospium Chloride, 
since the test formulation of trospium chloride resulted in highly variable pharmacokinetic 
profiles to the reference formulation. After a single dosage, the two formulations are expected 
to result in highly variable efficacy for the treatment of urinary incontinence. Therefore it can 
be concluded that test and reference products are biologically not equivalent under fasting 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER-VIII 
APPENDIX-I 
ACTIVITIES SCHEDULE 
Study phase 
 
Activity 
Screening 
With in 28 days 
of dosing 
Check-in day Dosing day 
Informed consent X X  
Medical history and 
demographic data 
X   
Physical examination X   
ECG (12-lead) X   
Vital signs measurement X   
Hematology X   
Urine analysis X   
Clinical chemistry X   
Serology(HIV-I&II, hepatitis 
B&C, RPR) 
X   
Urine drug screening ethanol, 
benzodiazepines, 
cannabionoids, amphetamines, 
cocaines, opiates (period-I) 
 X  
Record of concomitant 
medication 
 X X 
Check in procedures  X  
Alcohol screening(periods I&II) X X  
Confinement in study unit  X X 
Drug dosing   X 
PK blood sampling   X 
Adverse events monitoring  X X 
  
 
 
 
 
APPENDIX-II 
Pre-Study Laboratory Safety Evaluation Parameters 
Clinical chemistry 
S.No. PARAMETER REFERENCE 
INTERVALS 
UNITS 
1 Random blood glucose 70 to170 mg/dl 
2 Urea 15 to 40 mg/dl 
3 Creatinine 0.6 to 1.5 mg/dl 
4 Total bilirubin 0 to 1.0 mg/dl 
5 SGPT(ALT) 30 to 65 U/L 
6 SGOT(AST) 15 to 37 U/L 
7 Alkaline phosphatase(ALP) 50 to 136  U/L 
8 Albumin 3.7 to 5.3  g/dl 
9 Sodium 136 to149 mEq/L 
10 Potassium 3.8 to 5.2 mEq/L 
 
 SEROLOGY 
SEROLOGY SCREENING INDICATION 
HIV-1&2 HIV ANTIBODIES AIDS 
Abs antigen& HCV HEPATITS B& HEPATITIS C VIRUS 
RPR Test SYPHILIS 
 
HAEMATOLOGY 
S.No. PARAMETER REFERENCE 
INTERVALS 
UNITS 
1 Total W.B.C 4000 to 1100 /cmm 
2 Total R.B.C 4.5 to 6.5 mil/cu mm 
3 Hemoglobin 14 to 18 gms% 
4 HCT(PCV) 40 to 54 Vol% 
5 Neutrophils 40 to 75 % 
6 Lymphocytes 20 to 40 % 
7 Eosinophils 01 to 06 % 
8 Monocytes 2 to 8 % 
9 Basophils 0 to1 % 
10 Platelets 104 to 400 x 103 /cmm 
11 ESR(1st hr) 0 to 15 Mm 
URINE ANALYSIS 
PARAMETER 
Physical examination 
Color  
Transparancy 
Specific gravity 
Ph 
Chemical examination 
Glucose  
Protein  
Ketones 
Blood 
Urobilinogen 
Bilirubin 
Microscopical examination 
Pus cells 
RBC’s 
Epithelial cells 
Crystals 
Casts 
Others 
 
 
  
 
 
 
 
 
APPENDIX-III 
MEAL MENU FOR SUBJECTS PARTAKING 
 IN THE PRIMIDONE STUDY  
 
Pre-study dinner (Standard meal)Rice with one curry, dal, 
sambar, rasam, curd and papad 
Break fast  ------------------------ 
Lunch Standard meal 
Snacks Two somosa 
Dinner  Standard meal 
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